IASLC 2015 Annual Report

IASLC 2015

I N T E R N AT I O N A L A S S O C I AT I O N F O R T H E S T U D Y O F L U N G C A N C E R

Annual Report Ofcial Publication of the International Association for the Study of Lung Cancer

www.jto.org

Journal of Thoracic Oncology Volume 11, Number 2, February 2016

WW W.I AS LC

.ORG

Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief

WELCOME TO THE IASLC 16TH WORLD CONFERENCE ON LUNG CANCER

ram Book g o r P e c n e r Confe FOLLOW US FOLLOW US

R @IASLC ON TWITTE OK ON FACEBO

5 #WCLC201

JTHO_v11_i2_COVER.indd 1

MEM BECOME A

C BER OF IASL

ASLC.ORG VISIT WW W.I

24-12-2015 16:35:07

3 ANNUAL REPORT 2015

Table of Contents Introduction

4

Organization Structure

5

Membership

10

Communications

12

Fellowships

14

Educational Activities

16

Publications

19

Meetings

26

Awards

34

Sponsors and Advocacy Partners

38

Strategic Plan

39

IASLC Foundation

44

Future Perspective

46

IASLC in Publications

47

4 IASLC

Introduction Thanks to the hard work of our dedicated staff and the worldwide support of our members, 2015 was a banner year for the IASLC and for progress in lung cancer treatment.

Lung cancer remains a major global health problem.

Worldwide, more than 1.8 million individuals are diagnosed with the disease, which causes 1.6 million deaths, every year.

However, as we saw in 2015, major scientific advancements offer new hope to many lung cancer patients.

While the survival rate for many with lung cancer remains low, new targeted therapies and immunotherapies have the ability to change those statistics. Just this year, two immunotherapy drugs were approved by the U.S. FDA for lung cancer therapy. Immunotherapy continues to demonstrate very encouraging results, particularly in patients who have failed first-line therapy. Lung cancer screening with low-dose computed tomography (CT) has been demonstrated to reduce the lung cancer mortality by 20 percent in highrisk individuals. New advancements in molecular biology provide knowledge of heterogeneity of lung cancer, leading to personalized therapy. As we identify more subgroups it will have a dramatic effect of creating even more specific targeted therapies. All this has transformed lung cancer research and treatment into a role model for modern cancer treatments.

Among the major highlights from 2015 are the completion of two of IASLC’s global initiatives: The 8th Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer, this time including the thymus and esophagus, and the 2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition). Congratulations to all those involved in these very significant projects.

In 2015, we smoothly transitioned our journal, Journal of Thoracic Oncology, to a new publisher, Elsevier. The first issue published by Elsevier debuted in January 2016.

Never in our history has the IASLC enjoyed the outreach we had in 2015; our accomplishments vaulted our membership to a record high of more than 5,000 members in more than 100 countries. In addition to our successful webinars in both the U.S. and Europe, the IASLC School of Thoracic Oncology arranged several Live Learning programs, designed for fellows and junior faculty members in particular.

We enjoyed incredible success in all our 2015 meetings, notably the World Conference on Lung Cancer (WCLC) in Denver which gathered over 6,000 participants from nearly 100 countries and showcased many new advances in lung cancer science. We also launched more focused, smaller meetings, such as the Small Cell Lung Cancer meeting

and the consensus meeting on Management of EGFR Mutant NSCLC. The new IASLC Mentorship Award provided experienced IASLC mentors to 13 fellows during the WCLC. After the conference, they spent one week at a U.S.-based academic institution.

Because of the rapid pace of the progress in lung cancer, our molecular guidelines committee is already working to revise the IASLC/CAP/AMP Guidelines for Molecular Testing in NSCLC, new revisions of the ALK Atlas, which will now include ROS1, and development of a PD-L1 Atlas, which should help physicians and patients select the most appropriate immunotherapy treatment. While immunotherapy emerged as a promising treatment for lung cancer, the predictive assays related to this raised issues which the IASLC, together with other organizations, took the lead to solve through a coordinated Blueprint Project in collaboration with industry partners.

A core value for the IASLC is to develop and educate the next generation of investigators. Our generous members and outside donors gave strong support to the IASLC Foundation in 2015 and we look forward to expanding the Foundation and its support for young investigators to continue preventive and therapeutic scientific developments worldwide in the years to come.

We already have our sights set high for 2016. We will expand on our 2015 accomplishments with an additional emphasis in Asia and we will launch a new magazine that will include commentaries on all aspects of lung cancer science and management. The IASLC is also expanding our staff and office space to meet the growing demand for our support.

At the conclusion of this successful year, we thank our members and our staff for their commitment to the IASLC and to our mission to reduce lung cancer mortality all over the world.

Fred R. Hirsch, MD, PhD David P. Carbone, MD, PhD Chief Executive Officer President

5 ANNUAL REPORT 2015

Organiza on

President

President Elect

USA 2015-2017

Italy 2015-2017

Past President Tony Mok Hong Kong 2015-2017

Past President United Kingdom 2013-2015

Chief

Treasurer USA

USA 2013-2017

Alex Adjei USA 2011-2015

USA 2011-2015

Germany 2011-2015

Tetsuya Mitsudomi Japan 2011-2015

Japan 2011-2015

Silvia Novello Italy 2011-2015

Thailand 2011-2015

USA 2013-2017

USA 2013-2017

United Kingdom 2013-2017

i France 2013-2017

Japan 2013-2017

Switzerland 2013-2017

China 2013-2017

Australia 2015-2019

USA 2015-2019

Japan 2015-2019

Austria 2015-2019

Germany 2015-2019

Japan 2015-2019

USA 2015-2019

USA 2015-2019

6 IASLC

IASLC Staff

Position

Name

Chief Executive Officer Director of Education, Corporate Relations and Governance Director of Finance Director of Membership Director of Communications Scientific Projects Manager CME Education Coordinator JTO Managing Editor Projects Specialist Data and Technical Analyst Scientific Projects Specialist Asian Office

Fred R. Hirsch Pia Hirsch John Skadow Kristin Richeimer Jeff Wolf Murry Wynes Paul Silvey Mary Todd Becky Bunn Michelle Garcia Jacinta Wiens Vengie Lau

IASLC Committees (2015-2016) Committee

Chair

Past-Chair

2015 Accomplishments

Awards

David Carbone

Tony Mok

Bylaws

To Be Announced

Career Development and Fellowship

Ben Solomon

Martin Edelman/ Benjamin Besse

The Committee reviewed and ranked several Fellowship applications during 2015, evaluating young researchers in order to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine worldwide. In the coming year more awards will be reviewed and selected and the Committee will develop Career Development initiatives for IASLC.

Communications

Ross Soo

Anne Tsao

The Communications Committee played a key role in leading communications efforts for the 16th World Conference on Lung Cancer in Denver, helped guide promotional efforts for articles in the Journal of Thoracic Oncology (JTO), improved the delivery of IASLC’s monthly newsletter and provided editorial assistance for the daily newspaper at the WCLC.

Education

Federico Cappuzzo

Suresh Ramalingam

The Committee developed multidisciplinary curriculum for fellows and young investigators which is posted on the IASLC website. The Committee also evaluated requests for IASLC endorsed meetings and developed Live Learning Programs which were initiated in 2015 and will continue in the future.

Advanced Radiation Therapy (ART)

Laurie Gaspar Francoise Mornex

Hak Choy

This Subcommittee of the Education Committee continued the growth and expanded the IASLC webinar program, which started in 2012, worldwide.

Continuing Medical Education (CME)

Ramaswamy Govindan

Ethics

Thierry Marie Jahan

Eduardo Richardet/ Thierry Marie Jahan

In 2015, the Ethics Committee worked to help streamline the Conflict Of Interest submission process for the Board, Committee Members and all IASLC volunteers. The Committee seeks to be proactive on emerging issues and best practices around the world.

Finance

David Gandara

Fred R. Hirsch

Ensured that the IASLC made responsible and sound financial decisions.

Selected the 2015 IASLC Distinguished Award winners.

This Subcommittee of the Education Committee ensures adherence to CME rules, identifying ambassadors to monitor all IASLC meetings.

7 ANNUAL REPORT 2015

Membership

Luis Raez

Surish Senan

The Membership Committee oversaw another record year of IASLC membership in 2015. Volunteers from the Membership Committee served as ambassadors at the IASLC Exhibit Booth at various meetings and also worked to introduce new partner societies to IASLC for joint membership offers. The Committee expanded the IASLC free Fellow Membership program to allow group registration and will continue to encourage global growth in all regions and sub-specialties, particularly those currently under-represented in IASLC Membership, such as Radiation Oncology, Pulmonology, Pathology, and Nursing and Allied Health Professions.

Nominating

Joan Schiller

Kathy Albain

Selected the slate of potential 2015-2017 Board of Directors candidates.

Nurses & Allied Health Professionals

John White

Patricia Hollen

The Committee promoted a Resource Center which received nearly 10 percent of all IASLC.org website traffic March-December 2015, developed an agenda for N & AHP sessions completed for the 2015 WCLC Conference and wrote a manuscript, “Supportive care in lung cancer: Milestones over the past 40 years,� recently published in the JTO.

Pathology

Yasushi Yatabe

Andrew Nicholson

Together with the WHO, the Pathology Committee developed the new WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.

Patient Advocacy

Glenda Colburn

Glenda Colburn

The Committee launched several new initiatives, mostly focused on WCLC in 2015, including a Patient Advocacy Track at WCLC, unique registration rates for advocates, survivors and advocacy organizations, creating patient local liaisons and advocacy travel grants.

Prevention, Screening & Early Detection

To Be Announced

Nir Peled

Publications

David Spigel

Harvey Pass

Staging

Ramon Rami-Porta

Peter Goldstraw

The Staging Committee developed the 8th Edition of the Staging of Lung Cancer. Several publications have already been published in the JTO.

Tobacco Control/ Smoking Cessation

Michael Cummings

Carolyn Dresler

The Committee produced a monthly JTO section on global tobacco control and smoking cessation. The WCLC 2015 had the most comprehensive tobacco control and smoking cessation program for any world conference, including the launch of a Committee-updated IASLC Statement on Tobacco Control and Smoking Cessation. The IASLC, at the recommendation of the Committee and in association with dozens of other societies, signed onto multiple policy letters related to tobacco control in 2015. Educational Tobacco Exhibits produced by the Medical University of South Carolina and the Roswell Park Cancer Institute were displayed at multiple IASLC meetings. The Committee sponsored two webinars in 2015. A brochure on smoking cessation and tobacco control for physicians was started by the Committee and will be launched in 2016.

Asia Pacific Lung Cancer

Sumitra Thongprasert

The Committee held an all-day sold out workshop on planning for the implementation of lung cancer CT screening internationally at WCLC 2015 and had a comprehensive prevention, screening, and early detection program because of the work by the committee and its members.

Committee members wrote a document on establishing a lung cancer screening clinic, with the aim of helping centers through a standardized approach. The Committee is also working on documents and tools on the website for risk assessment, nodule management, and information on what data should be collected. Moving forward, the Committee will address ground glass opacity management and the creation of an image atlas in order to standardize and support better clinical decisions.

The Publications Committee assisted in the decision to move to a new publisher for the Journal of Thoracic Oncology, taking part in the decision to move the journal to Elsevier; opened discussions with Elsevier about a new edition of the IASLC textbook; helped to develop articles detailing the progress in lung cancer in 2015 for the JTO; and looks forward to helping with the launch of the new magazine, IASLC Lung Cancer News, in 2016.

Planned the APLCC meetings in Southeast Asia.

8 IASLC

IASLC Council of Regents Regent Area Australasia Brasil Canada Central America and Mexico Central Europe China Europe (1) Europe (2) Europe (3) Europe (4) Greece Gulf States and Arabia Indian Sub-Continent Japan (1) Japan (2) Korea North America North America North America North America Russia South-East Asia Southern Africa Spanish South America Taiwan Turkey UK and Ireland

Regent Name

Specialty & Location

Nick Pavlakis Mauro Zamboni Gail Darling (Chair 2012-2015) Oscar Arrieta Gyula Ostoros Yi-Long Wu Rudolph Huber Lucio Crino Paul de Leyn Cecile le Pechoux Ioannis Gkiozos Khaled Al-Kattan Digembar Behera Shuji Sakai Ichiro Yoshino Young Tae Kim Heather Wakelee Charles Powell Brian Lally Gerard A. Silvestri Valeriy Breder Ibrahim Wahid Tony Linegar Eduardo Richardet James Chih-Hsin Yang Deniz Yalman Richard Booton

Medical Oncology, Sydney Thoracic Surgery, Rio de Janeiro Thoracic Surgery, Toronto Medical Oncology, Mexico City Medical Oncology, Budapest Thoracic Surgery, Guangzhou Medical Oncology, Munich Medical Oncology, Perugia Thoracic Surgery, Leuven Radiation Oncology, Paris Pulmonology, Athens Thoracic Surgery, Riyadh Pulmonology, Chandigarh Thoracic Surgery, Tokyo Thoracic Surgery, Chiba Thoracic Surgery, Seoul Medical Oncology, Stanford Pulmonology, Mt. Sinai Radiation Oncology, Miami Pulmonology, Charleston Medical Oncology, Moscow Radiation Oncology, Kuala Lumpur Thoracic Surgery, Cape Town Medical Oncology, Cordoba Medical Oncology, Taiwan Radiation Oncology, Izmir Pulmonology, Manchester

IASLC Task Forces Task Force Industry Quality and Value

Chair(s) Giorgio Scagliotti Paul A. Bunn, Jr. Ronan Kelly

Past Chair Rolf Stahel

9 ANNUAL REPORT 2015

Organization Overview Members – Those belonging to the IASLC come from a wide range of fields and backgrounds. Our organization brings together clinical practitioners, scientists, patient advocates, nurses and industry executives united in the goal of prevention, screening, imaging, diagnosis and treatment of thoracic malignancies. We rely on the expertise of our members as we work to find new ways to collaborate and share the most timely and relevant scientific and clinical information around the world. Leveraging these resources positions the IASLC as the premier global source of information on thoracic malignancies. Members devote their time to leading IASLC sponsored meetings and conferences, take active roles in various committees, provide presentations on cutting-edge basic, translational, and clinical science and engage in robust interactions to further the IASLC mission.

Board of Directors – The IASLC Board of Directors is multidisciplinary and each member brings an abundance of clinical and scientific expertise, along with a broad base of experience with other societies and familiarity with institutional leadership. IASLC board members promote ongoing growth in programs and new initiatives through their strategic guidance as well as their operational and financial oversight.

Headquarters Staff – Under the leadership of the CEO, the staff implements a wide range of education, membership, communication, outreach, fundraising and scientific programs for the organization. From facilitating many worldwide conferences to producing webinars, publishing books and digital applications, collaborating with committees and members, disseminating the latest scientific advances and working with the media globally, the staff distributes the best and latest information to our members and the public across the globe. The staff works diligently to keep contact information up-to-date and is accountable for the management of IASLC finances, including obtaining sponsorships for various activities and events. The staff supports, gives expert advice and helps implement decisions made by IASLC committees and the Board of Directors.

10 IASLC

Membership IASLC Membership Reaches Record High of 5,000 Members IASLC staff set and attained a landmark goal of 5,000 active members in 2015, an increase of 47 percent compared with 2014, by actively engaging with current members, creating new and innovative ways of reaching new potential members, and enrolling a record of more than 1,500 new members this year.

Several key initiatives should be credited for this growth: »» IASLC Membership Booth Promotions and Partner Society Offers: Launched as a pilot program in 2015, new members from these initiatives amount to an estimated 10 percent of total members. With IASLC’s Membership Booth presence at societies for Thoracic Surgery, Pulmonology and Medical Oncology in Europe and North America, we continue to increase IASLC exposure in under-represented specialties and regions of the world. »» WCLC 2015 Registration: While membership historically increases during WCLC years, IASLC improved the data sharing and registration process this year to capture membership as individuals completed WCLC registration. In addition, many new members took advantage of the multi-year discount offer at the WCLC in Denver, Colorado. »» Retention & Recovery: IASLC retained and recovered 88 percent of former members and lapsed members, which is an increase over past years’ retention rate. »» Early-Career Members: Increased promotion of the free Fellow membership, available to Fellows, Residents and Trainees in all disciplines led to growth in this member category. We encourage all members to “Invite-a-Fellow” or utilize the Group Fellow Registration to make sure early career physicians and investigators can benefit from this incredible value. »» Improved Technology: Improvements to the member database and email marketing software provided better member data and allowed more frequent notices to be distributed to lapsed members.

2015 Members by Specialty Cancer Research/ Basic Sciences, 6%

Pathology, 5%

Radiation Oncology/ Diagnostic Radiology, 9% Other, 11% Pulmonary Medicine, 14%

Nursing, 4%

Medical Oncology, 32% Thoracic Surgery, 20%

2015 Members by Region Rest of the World, 6%

Latin America, 6%

North America, 35%

Europe, 23% Asia, 28%

11 ANNUAL REPORT 2015

Attracting Members from the Entire Multidisciplinary Team IASLC established a goal of educating the entire team of providers for lung cancer patients. To further that goal, IASLC updated its member communications to include language to make it clear that IASLC membership is valuable to anyone who is involved in lung cancer around the world.

IASLC actively seeks to increase its membership among: • • • • •

Pathologists Diagnostic radiologists Nurses and allied health professionals Community practitioners Industry professionals

The series of Advanced Radiation Technology (ART) Webinars provided a unique vehicle to attract new members in radiation oncology, and our partnerships with subspecialty societies around the world increase the visibility and membership of IASLC. Member Engagement and Benefits In 2015, the IASLC introduced the membership card and sent one to all active members. Many members brought their cards to the membership booth to get an IASLC member pin and invited colleagues to join. In addition, we revived the printed Member Directory in 2015 and all members could choose to receive one in the mail. For the first time, we launched the IASLC Virtual Library with educational content from WCLC 2015 and 2013, making it available to members on the IASLC website through their IASLC membership login. Members who did not attend the WCLC could also purchase access to the WCLC 2015 Virtual Meeting for $99 USD. Additionally, all active members can access the WCLC 2013 content free of charge. Members and meeting attendees were also eager to pick up the 8th Edition TNM Staging Card Proposals at many meetings around the world.

The Years Ahead - Collaboration Welcome!

The IASLC encourages members, partner societies and industry partners to pursue beneficial collaborations.

A high priority for early 2016 is the official launch of the Corporate Membership Program. The IASLC Membership Department and Membership Committee remain committed to continued aggressive growth, particularly in under-represented specialties and regions of the world. We welcome member suggestions and ideas for collaborations, which can be submitted anytime to the IASLC Membership Committee, Membership Director or the IASLC Regent in your location. We thank you for your commitment to conquering thoracic cancers worldwide!

New members from the following societies can receive additional discounts!

12 IASLC

Communications In 2015, the IASLC’s communications efforts achieved greater reach than ever before, garnering media attention and headline stories around the world. During the year, we published more than 60 news releases, focusing on scientific advancements, lung cancer awareness and the 2015 WCLC top abstracts and awards. Our media efforts included a signed letter to the FDA commissioner addressing our community’s concerns with regulatory action that prevents research on vital electronic nicotine delivery systems (ENDS), and a signed letter to the American Red Cross asking the organization to stop accepting money from the tobacco industry. IASLC has great plans for the future of our communications, including better and more targeted campaigns and ways to ensure our members stay up-to-date on the latest in our industry.

Figures at-a-Glance

WCLC 2015 During the 16th World Conference on Lung Cancer in Denver, IASLC partnered with a public relations firm to expand our reach exponentially. Our WCLC 2015 efforts included more than two dozen press releases, hundreds of emails to media professionals, four press conferences – one for each day of the WCLC, and These efforts resulted in more than on-site interviews with multiple TV multiple interviews with news 1 billion impressions and more than stations and an article on the front organizations. $400,000 in AdValue, including page of a major newspaper.

13 ANNUAL REPORT 2015

Lung Cancer Awareness Month November is recognized as Lung Cancer Awareness Month in many countries, and the IASLC once again participated by hosting events, sharing successes in lung cancer treatment with the media and collaborating with international members to raise awareness of lung cancer. The highlight of our efforts included a Lung Cancer Awareness Forum at the IASLC headquarters where several lung cancer patients joined with local doctors and health professionals to share their stories and to collaborate by sharing information.

It was an emotional and rewarding experience for all and the staff plans to hold similar events in the future. Additionally, we participated in Lung Cancer Social Media’s Twitter chat, featuring answers by IASLC CEO Dr. Fred R. Hirsch. We also announced the launch of a new initiative by IASLC to improve communications between patients and health professionals. Look for more information on this initiative in the coming year. Our messaging this November focused on spreading regional facts about lung cancer and on dispelling lung cancer myths. The IASLC also succeeded in getting media outlets to do several stories to help raise lung cancer awareness and heard from many IASLC members from across the globe about local events they participated in to raise awareness.

Newsletter Key to keeping in close touch with our members is the distribution of a newsletter, delivered by email to all members each month. The newsletter includes updates from the IASLC CEO and the President, as well as information on all upcoming events, new initiatives and abstract deadlines. Fellowship awards, key JTO articles and advocacy efforts can also be found featured in the newsletter. To report in detail on global activities, the IASLC Regents also offer information about initiatives in their regions.

Social Media 2015 Social Media Growth

3,000 2,000 December January

1,000 0

Twitter

IASLC

JTO

Facebook Facebook January

December

As more and more members and journalists expand their use of social media, the IASLC sharpens our use of technology to provide quick, streamlined information. IASLC’s social media numbers consistently rose during 2015 with the IASLC Facebook page seeing a growth from less than 1,500 likes and ending the year with more than 1,900. The JTO Facebook page also enjoyed year-to-year growth, starting with more than 2,300 likes and ending with more than 2,500. The IASLC Twitter account gained nearly 700 new followers during the year and reached a high point during September with 134,000 Tweet impressions and nearly 5,000 profile visits.

14 IASLC

Fellowship/Young Investigator Awards 2015 – 2016 Fellowships remain a key part of the IASLC mission. In 2015, IASLC continued its support for young researchers in order to reward scientific excellence and to encourage innovative research in lung cancer prevention as well as in clinical and translational medicine worldwide. The IASLC accepted applications for Fellowship and Young Investigator Awards in January, with candidates representing North America, Asia and Europe awarded research funding after competing with a global pool of applicants.

Global submissions to our fellowship awards included many excellent candidates, evaluated by a Scientific Review Panel for their merit, innovation and potential impact on the future management and treatment of lung cancer. In 2015, a joint collaboration between Boehringer Ingelheim China and IASLC enabled a fellow from Shanghai, China to come to the United States to perform a 1-year research project.

Mark M. Awad Dana-Farber Cancer Institute, USA Mentor & Institution: Young Investigator DanaFarber Cancer Institute, USA Project: Development of Assays to Detect Antibody and T-cell Immune Responses to Anaplastic Lymphoma Kinnsae (ALK) in Non-Small Cell Lung Cancer (NSCLC) Patients

Jill E. Larsen QIMR Berghofer Medical Research Institute, Australia

Puey Ling Chia The Austin Hospital, Australia Mentor & Institution: Thomas John The Austin Hospital, Australia Project: Characterization of the tumour microenvironment in mesothelioma for immunoligical and oncogenic targeted therapies

Colin Lindsay Institut Gustave-Roussy, France

Yayi He (Boehringer Ingelheim Chinese Fellowship & IASLC Fellow) Tongji University, Shanghai, China Mentor & Institution: Fred R. Hirsch University of Colorado, USA Project: Study on acquired resistant mechanisms to afatinib (BIBW2992) in lung adenocarcinoma with HER2 mutations

Yoichiro Mitsuishi Dana-Farber Cancer Institute, USA

Mentor & Institution: Young Investigator QIMR Berghofer Medical Research Institute, Australia

Mentor & Institution: Benjamin Besse Institut Gustave-Roussy, France

Mentor & Institution: Matthew Myerson Dana-Farber Cancer Institute, USA

Project: Characterizations of “cooperative” mutations for their potential as acquired vulnerabilities in KRAS-driven non-small cell carcinoma

Project: Assessing the clinical significance of EPCAM-negative circulating tumour cells in non-small cell lung cancer

Project: Chemical screen for agents that degrade the lung cancer oncoprotein Nrf2

15 ANNUAL REPORT 2015

Sara Pilotto University of Verona, Italy Mentor & Institution: Emilio Bria University of Verona, Italy Project: Immune checkpoint regulators and driving gene mutations as outcome predictors for resected squamous cell lung cancer

Silvestre Vicent Center for Applied Medical Research (CIMA), Spain Mentor & Institution: Young Investigator Center for Applied Medical Research (CIMA), Spain Project: Dissecting the functional role of Fos-like antigen 1 (FOSL1) in KRAS-driven Lung Cancer

Adrian G. Sacher Dana-Farber Cancer Institute, USA Mentor & Institution: Geoffrey R. Oxnard Dana-Farber Cancer Institute, USA Project: Quantitative Plasma Genotyping as an Integrated Biomarker in Advanced NSCLC Therapy

Kenichi Suda Kinki University, Japan Mentor & Institution: Young Investigator University of Colorado, USA Project: Foundational investigation to optimize 3rd generation EGFR-TKI treatment – analyzing heterogeneity of resistance and overcoming resistance

Piyada Sitthideatphaiboon (APLCC & IASLC Fellow) Chulalongkorn University, Thailand Mentor & Institution: Virote Sriuranpong and Trairak Pisitkun, MD Anderson Cancer Center, USA Project: Proteomic signature for the difference in chemo­therapy sensitivity between mutant EGFR and wild type EGFR in non-small cell lung cancer

IASLC would like to thank the following supporters of the IASLC Fellowship/Young Investigators Program: »»AstraZeneca »»Boehringer Ingelheim »»Bristol-Myers Squibb »»Celgene »»Daiichi Sankyo »»Eli Lilly »»Genentech »»Pfizer »»Prevent Cancer Foundation

16 IASLC

Educational Activities To broaden the availability of educational offerings, the IASLC expanded its number of Continuing Medical Education (CME) accredited programs in 2015, offering 23 webinars on diverse topics and organizing multiple Live Learning events. Members around the world now have the ability to learn in person at meetings and Live Learning events, and to learn from their offices through webinars. The IASLC Global Curricular Framework continues to serve as a resource for lifelong learning.

IASLC Webinar Programs - 2015 Title: Best of 2014 Lung Cancer Research

and High Priority NCI Lung Cancer

Trials – CME Speaker: Roy S. Herbst, MD, PhD Moderator: Ramaswamy Govindan, MD –

Program Chair Date: January 20, 2015

Title: New Therapies Are Coming for

Malignant Pleural Mesothelioma – CME Speaker: Lee M. Krug, MD Moderator: Ramaswamy Govindan, MD –

Program Chair Date: April 2, 2015

Title: Improving therapeutic outcomes for

lung cancer patients: addressing the

overwhelming evidence about tobacco

use and cancer treatment. (Tobacco

Control Committee Webinar) Speaker: Graham Warren, MD, PhD Moderator: Carolyn Dresler, MD Date: January 21, 2015

Title: Evolving Role of PD-1/PD-L1 Inhibitors

in the Clinical Management of NSCLC – CME Speaker: Edward Garon, MD Moderator: Ramaswamy Govindan, MD –

Program Chair Date: June 17, 2015

Title:

Speakers:

Date:

Advances in NSCLC: Approaches to the Management of TKI Resistance Jonathan Goldman, MD and Heatheer Wakelee, MD February 24, 2015

Title:

Speaker: Date:

Current Role of Immunotherapy for Lung Cancer – CME Scott N. Gettinger, MD June 25, 2015

Title: Chemotherapy Options for Metastatic

Lung Cancer – CME Speaker: Mark A. Socinski, MD Moderator: Ramaswamy Govindan, MD –

Program Chair Date: March 4, 2015

Title: Advanced Radiation Technology

Committee Live Webinar Series Making Progress in Stage III NSCLC

Management – CME Speakers: David Ball, MD

Michael MacManus, MD Moderator: Francoise Mornex, MD – Program Chair Date: July 9, 2015

Title: E-Cigarettes: Friend or Foe?

(Tobacco Control Committee) Speakers: Maciej Goniewicz, PhD

Ben Toll, MD Moderator: Matthew Steliga, MD Date: April 1, 2015

Title: Biomarkers and Personalized Medicine

for Patients with Lung Cancer – CME Speaker: Prof. Keith Kerr, MD Moderator: Ramaswamy Govindan, MD –

Program Chair Date: July 14, 2015

17 ANNUAL REPORT 2015

Title: Combined Modality Treatment of

Stage III NSCLC – CME Speaker: Suresh Senan, MD Moderator: Ramaswamy Govindan, MD –

Program Chair Date: July 20, 2015 Title: Advanced Radiation Technology

Committee Live Webinar Series:

Follow-up of patients after SABR

(stereotactic ablative radiotherapy)

for early stage NSCLC-A Primer for the

Multidisciplinary Team – CME Speakers: David Palma, MD

Suresh Senan, MD Moderator: Francoise Mornex, MD – Program Chair Date: July 21, 2015 Title: EGFR TKIs: What is New? – CME Speaker: Lecia Sequist, MD Moderator: Ramaswamy Govindan, MD –

Program Chair Date: August 26, 2015 Title: Speaker: Date:

Surgical Standards for NSCLC – CME Walter Weder, MD September 1, 2015

Title: Advances in Radiation Therapy for

Non-Small Cell Lung Cancer – CME Moderator: Francoise Mornex, MD, PhD Speakers: Yasushi Nagata, MD

Yong Chan Ahn, MD Date: September 25, 2015 Title: Ongoing Clinical Trials for Patients

with Advanced Lung Cancer – CME Moderator: Ramaswamy Govindan, MD Speaker: David Gandara, MD Date: October 1, 2015

Title:

Speaker: Date:

IASLC WHO Pathology Classification 2015 – CME Andrew Nicholson, MD October 8, 2015

Title: ASCO/IASLC 2015 Lung Cancer

Updates for Radiation Oncologists – CME Moderator: Laurie Gaspar, MD Speakers: Clifford Robinson, MD

Saima Waqar, MD Date: October 12, 2015 Title: Speaker: Date:

Staging of Lung Cancer – 2015 – CME Ramon Rami-Porta, MD October 14, 2015

Title: WCLC 2015 UPDATE Moderator: Ramaswamy Govindan, MD Speaker: Suresh Ramalingam, MD Date: October 21, 2015 Title: Speaker: Date:

Lung Cancer in Women – CME Silvia Novello,MD November 10, 2015

Title: Challenging Cases in Early Stage

Non-Small Cell Lung Cancer – CME Moderator: Ramaswamy Govindan, MD Speaker: Heather Wakelee, MD Date: November 18, 2015 Title: Challenging Cases in Advanced Stage

Non-Small Cell Lung Cancer – CME Moderator: Ramaswamy Govindan, MD Speaker: Anne Tsao, MD Date: December 8, 2015

18 IASLC

Live Learning IASLC hosted three Live Learning events on multidisciplinary topics (pulmonology, medical oncology, surgery, radiation oncology and pathology) in 2015. These workshops were open to physicians and allied health professionals involved in the care of patients with lung cancer and were particularly suited for early career physicians and trainees. These were held in New York, Atlanta and San Francisco with huge success. The IASLC plans to continue this project in 2016.

In December 2014, CHEST, the American Society for Clinical Pathology, the National Comprehensive Cancer Network® (NCCN®), IASLC and The France Foundation developed a live learning experience called GAIN (EnGAging An Interdisciplinary Team) for NSCLC Diagnosis, Personalized Assessment and Treatment. Through case-based discussions and interactive simulations, GAIN interdisciplinary summits sought to address specific unmet needs and clinical gaps in the care of patients with locally advanced and metastatic non-small cell lung cancer (NSCLC). The goal of the summits was to advance the knowledge, competence, and performance of a team of interdisciplinary specialists who are currently responsible for appropriate staging, mediastinal lymph node assessment, tissue acquisition, biomarker analysis and immunotherapy in patients with NSCLC. Throughout 2015, 12 GAIN events were held: eight in the U.S. and four in Europe.

Global Curricular Framework The Education Committee developed and maintains a Global Curricular Framework for thoracic cancer, categorized according to relevant subspecialties of the IASLC membership. Each of these subspecialty curricula was based on the structure of the IASLC-sponsored Textbook of Thoracic Oncology. This curriculum-based framework is designed to serve as a foundation for a “lifelong learning” culture in the IASLC. It is envisioned that every IASLC-sponsored educational event will be aligned with this curricular framework, as it will be used prospectively to identify education gaps, and to plan and develop materials for workshops, webinars, and IASLC-sponsored live educational events. The curricular framework will also serve as the reference classification system (or taxonomy) for the planned IASLC online education portal, where subspecialty curricula will be used to organize content and tag materials. This curriculum-oriented education portal will also provide centralized access to archived live and distance learning activities, as well as performance improvement CME modules. For more information, please visit iaslc.org.

Global Curricular Framework Categories: »» Basic/Translational Science »» Medical Oncology »» Pathology

»» Pulmonary Medicine »» Radiation Oncology »» Thoracic Surgery

19 ANNUAL REPORT 2015

Publications The past year saw several of the IASLC’s initiatives come to fruition. We publicly unveiled these new publications at the 16th World Conference on Lung Cancer in September. All will help us in our mission to spread best practices around the globe and assist health professionals in their battle to conquer thoracic oncology worldwide.

New Staging System As announced at the WCLC, the publication of the Eighth Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer will provide physicians around the world access to new data to more precisely stage and treat cases of lung cancer. The data, collected by the IASLC Staging Committee, are planned for publication in 2016.

The IASLC helped publish cards that explain the different parts of the new staging system and widely distributed them at the WCLC. In 1998, IASLC established its Lung Cancer Staging Project, an effort to collect a significant, international database of lung cancer cases and their anatomical classifications. IASLC collected and published a large amount of data regarding the size of tumors, lymph node involvement and metastatic status which was then presented to the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) for evaluation.

Before the IASLC Staging Project, data collected for staging of lung cancer came from a smaller group of patients, almost exclusively based in the U.S. The new database, which will inform the Eighth Edition of the TNM Classification of Lung Cancer, consists of 94,708 patients diagnosed around the world from 1999-2010. The objective is to further explore and analyze the impact on prognosis of tumor size and of the different T descriptors; the prognostic significance of tumor burden in hilar and mediastinal lymph nodes; and the confirmation of the revised M1 categories (M1a and M1b) of the seventh edition of the classification along with the prognostic impact of number and anatomic location of metastases.

The precise clinical description of malignant neoplasms and histopathological classification may serve a number of related objectives: »» To aid the clinician in the planning of treatment »» To give some indication of prognosis »» To assist in evaluation of the results of treatment »» To facilitate the exchange of information between treatment centers »» To contribute to the continuing investigation of human cancer

20 IASLC

Analyses of the new database and the findings suggesting recommendations for the revision of the seventh edition of the TNM classification of lung cancer will be submitted to the Journal of Thoracic Oncology to make them available to the worldwide oncology community. The suggested recommendations and their supportive data will also be submitted to the UICC and the AJCC for their assessment and inclusion in their new staging manuals, due to be published in 2016. The new edition of the classification will then be enacted in January 2017.

2015 WHO Pathology Classification An additional IASLC global initiative showcased at the WCLC included the release of the 2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition). WHO Classifications represent a pathologic and genetic classification and grading of human tumors designed to be accepted and used worldwide. They provide standard criteria for pathology diagnosis, clinical practice, cancer registration, epidemiologic studies, clinical trials and cancer research.

The 2015 WHO Classification of Lung Tumors represents the culmination of a decade of remarkable advances in all lung cancer specialties including: pathology (histology, cytology, immunohistochemistry, molecular testing), clinical oncology, epidemiology, radiology and genetics. The rapid expansion of molecular and immunohistochemical tools provided a strong foundation for the classification and a rationale for reclassification of specific entities.

Accurate pathologic diagnosis and tissue management is now critical in lung cancer diagnosis and management. Historically, pathologists were charged with distinguishing between small cell carcinoma and non-small cell carcinoma, limiting their role. With therapeutic and genetic advances (particularly regarding targeted therapies in patients with driver mutations in EGFR, ALK, ROS1, BRAF and RET) where treatment strategies depend on histology and genetics, pathologists must now make more precise diagnoses and preserve tissue for molecular testing.

Previous WHO classifications did not focus on diagnosis in small biopsies and cytology, so this is a completely new aspect to this WHO Classification. Critical aspects of this include: »» New diagnostic criteria and terminology for lung cancer in small biopsies and cytology »» More accurate histologic subtyping »» Strategic management of small tissues »» Streamlining workflow for molecular testing »» Local multidisciplinary strategy for obtaining, processing and reporting these specimens.

21 ANNUAL REPORT 2015

New Statement on Tobacco Control & Smoking Cessation Stemming from the fact that the vast majority of lung cancer cases result from tobacco smoking, the IASLC issued a new statement on Tobacco Control and Smoking Cessation at the WCLC. The statement calls for higher taxes on tobacco products, comprehensive advertising and promotion bans of all tobacco products and product regulation including pack warnings.

As a key part of the statement, the IASLC Tobacco Control and Smoking Cessation Committee highlighted an estimate that showed that doubling the inflation-adjusted price of cigarettes could result in a 33 percent reduction in smoking prevalence. Many lowand middle-income countries can accomplish this by tripling the specific excise tax on tobacco. A low-specific excise tax on tobacco is the main reason cigarettes are about 70 percent cheaper in many low-income countries compared with high-income countries.

In the statement, the IASLC urges its members and others around the world to: »» Join together to forcefully implement the WHO’s Framework Convention on Tobacco Control which has among its key provisions increasing cigarette prices via taxation (to at least 70 percent of the retail price), prohibiting the sale of cigarettes to minors (less than 21 years of age), enacting and enforcing comprehensive cigarette marketing policies, eliminating tobacco use in public locations, mandating graphic warning labels on cigarette containers, implementing public education campaigns to discourage the use of cigarettes and providing tobacco cessation support. »» Adopt legal reforms that allow people who smoke and their families to use the judicial system to hold tobacco manufacturers civilly and criminally accountable for selling products that are deadly when used as intended. »» Support programs to prevent smoking initiation habits in children and in youth and recognize that any attempts to induce nicotine consumption in this population should be avoided. »» Implement tobacco cessation programs in their clinics, hospitals and cancer centers to assist their patients in achieving the best possible outcomes from their cancer treatment. »» Adopt policy measures that recognize the probable differences in the lung cancer risk of alternative nicotine delivery products. Adopting policies that favor less dangerous (non-combustible) forms of nicotine delivery over cigarettes would provide a powerful incentive for people who smoke to move away from cigarettes which in turn would have a profound impact on global lung cancer rates in the coming decades.

Read the full Statement on Tobacco Control and Smoking Cessation at www.iaslc.org/research-education/policies.

22 IASLC

Ofcial Publication of the International Association for the Study of Lung Cancer

www.jto.org

Journal of Thoracic Oncology Volume 11, Number 1, January 2016

Alex A. Adjei, MD, PhD, FACP, Editor-in-Chief

Journal of Thoracic Oncology The Journal of Thoracic Oncology, the official journal of the IASLC, is the primary educational and informational publication for topics relevant to the detection, prevention, diagnosis, and treatment of thoracic malignancies. JTO emphasizes a multidisciplinary approach, and includes original research (clinical trials and translational or basic research), reviews, and opinion pieces. It has a global author base and readership consisting of epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonary specialists, radiologists, pathologists and research scientists with a special interest in thoracic oncology.

In 2015, 913 original research articles were submitted with acceptance of 133, resulting in an acceptance rate of 14.6 percent. For all submission types, there were 1,276 manuscripts submitted and 216 were accepted, equating an acceptance rate of 16.9 percent. There were 193,387 full-text views and 240,207 website visits in 2015. The JTO was ranked 30 out of 211 for oncology and 7 out of 57 for respiratory system subject matter categories in the 2014 Journal Citation Reports. The 2014 Impact Factor was 5.282, down slightly from 5.8 in 2013. The 2015 Impact Factor is set to be released in July 2016.

JTHO_v11_i1_COVER.indd 1

08-12-2015 15:53:40

Starting in 2016, Elsevier becomes the new publisher of the JTO. Along with a new look, the move makes many new features available to our authors and readers: »» Share Link allows authors to freely distribute their published articles for 50 days »» Articles will be added to Scopus, the world’s largest abstract and citation database of peer-reviewed literature »» Accepted manuscripts will be posted within three days of acceptance »» Published findings can be highlighted with audio slide presentations.

“As the leading international lung cancer association, the IASLC is excited to expand the reach of the JTO and to ensure that medical professionals around the world have access to the cutting edge research being shared in this publication,” said Alex A. Adjei, MD, PhD, Editor-in-Chief of the JTO. “We are working closely with the Elsevier team to maximize the benefits that Elsevier can provide to authors and readers of the JTO. This will allow us to take advantage of synergies with Elsevier’s electronic infrastructure and extensive catalog of leading cancer publications.”

23 ANNUAL REPORT 2015

The Communications Committee, Murry Wynes, PhD, and the IASLC Science Department continue their efforts to promote the JTO through press releases sent to the media. This collaboration has resulted in coverage in The New York Times and other premier outlets thus furthering the educational outreach efforts of the IASLC. The next pages show the JTO articles featured in 2015.

JTO Articles Highlighted in Press Releases Re-evaluation of the role of post-operative radiotherapy and the impact of radiation dose for non-small cell lung cancer using the National Cancer Database Christopher D. Corso, MD, PhD; Charles E. Rutter, MD Lynn D. Wilson, MD; Anthony W. Kim, MD; Roy H. Decker, MD, PhD; Zain A. Husain, MD

Supportive care in lung cancer: Milestones over the past 40 years Alex Molassiotis, RN, PhD; Wilma Uyterlinde, NP, PhD; Patricia J. Hollen, PhD, RN, FAAN; Linda Sarna, RN, PhD; Patricia Palmer, RN, MS, AOCNS; Meinir Krishnasamy, RN, PhD

Perception of Lung Cancer Among the General Population and Comparison With Other Cancers Julien Mazières, MD, PhD; Jean-Louis Pujol, MD, PhD; Nikos Kalampalikis, PhD; Diane Bouvry, MD; Elisabeth Quoix, MD, PhD; Thomas Filleron, MD, PhD; Nathalie Targowla, MD; Denise Jodelet, PhD; Julie Milia, PhD; Bernard Milleron, MD

Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study Marco Lo Iacono, PhD; Valentina Monica, PhD; Luisella Righi, MD; Federica Grosso, MD; Roberta Libener, MD; Simona Vatrano, BS; Paolo Bironzo, MD; Silvia Novello, MD; Loredana Musmeci, MD; Marco Volante, MD; Mauro Papotti, MD; Giorgio V. Scagliotti, MD

Cost-Effectiveness of Multiplexed Predictive Biomarker Screening in Non-Small Cell Lung Cancer Dorothy Romanus, PhD; Stephanie Cardarella, MD; David Cutler, PhD; Mary Beth Landrum, PhD; Neal I. Lindeman, MD; G. Scott Gazelle, MD, PhD

24 IASLC

Baseline characteristics and mortality outcomes of NELSON control group participants and eligible non-responders Uraujh Yousaf-Khan, MD; Nanda Horeweg, PhD, MD; Carlijn van der Aalst, PhD; Kevin ten Haaf, MSc; Mathijs Oudkerk, PhD, MD; Harry de Koning, PhD, MD

Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma Zoltan Lohinai, MD; Mir Alireza Hoda, MD; Katalin Fabian, MD; Gyula Ostoros, MD, PhD; Erzsebet Raso, PhD; Tamas Barbai, MS; Jozsef Timar, MD, PhD, DSc; Ilona Kovalszky, MD, PhD; Mihaly Cserepes, MS; Anita Rozsas, MS; Viktoria Laszlo, PhD; Michael Grusch, PhD; Walter Berger, PhD; Walter Klepetko, MD; Judit Moldvay, MD, PhD; Balazs Dome, MD, PhD; Balazs Hegedus, PhD

The presence of asbestos in the natural environment is likely related to mesothelioma in young individuals and women from Southern Nevada Francine Baumann, PhD; Brenda J. Buck, PhD; Rodney V. Metcalf, PhD; Brett T. McLaurin, PhD; Douglas J. Merkler, MSc; Michele Carbone, MD, PhD

Impact of an Interactive Online Tool on Therapeutic Decision-Making for Patients with Advanced Non-Small Cell Lung Cancer Helen Chow, MD; Martin J. Edelman, MD; Giuiseppe Giaccone, MD; Suresh S. Ramalingam, MD; Timothy A. Quill, PhD; Andrew D. Bowser, PhD; Jim Mortimer, PhD; Wilma Guerra, PhD; Laurel A. Beckett, PhD; Howard L. West, MD; Primo N. Lara, MD; David R. Gandara, MD

Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small cell lung cancer Elyn H. Wang, BS; Charles E. Rutter, MD; Christopher D. Corso, MD, PhD; Roy H. Decker, MD, PhD; Lynn D. Wilson, MD, MPH; Anthony W. Kim, MD; James B. Yu, MD, MHS; Henry S. Park, MD, MPH

Randomised study on early detection of lung cancer with MSCT in Germany: results of the first 3 years of follow-up after randomization N. Becker, PhD; E. Motsch, MD; M.-L. Gross, MD; A. Eigentopf, BSc; C.P. Heussel, MD, PhD; H. Dienemann, MD, PhD; P.A. Schnabel, MD, PhD; M. Eichinger, MD; D.-E. Optazaite, MD; M. Puderbach, MD, PhD; M. Wielpütz, MD; H.-U. Kauczor, MD, PhD; J. Tremper, MD; S. Delorme, MD, PhD

FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small Cell Lung Cancer Woocheol Kwon, MD; Brandon A. Howard, MD, PhD; James E. Herndon, PhD; Edward F. Patz, Jr. MD

Increasing Physical Activity and Exercise in Lung Cancer: Reviewing Safety, Benefits, and Application Brett C. Bade, MD; D. David Thomas, MS; JoAnn B. Scott, BA; Gerard A. Silvestri, MD, MS

Hormone use, reproductive history and risk of lung cancer: the Women’s Health Initiative Studies Ann G. Schwartz, PhD, MPH; Roberta M. Ray, MS; Michele L. Cote, PhD; Judith Abrams, PhD; Robert J. Sokol, MD; Susan L. Hendrix, DO; Chu Chen, MS, PhD; Rowan T. Chlebowski, MD, PhD; F. Allan Hubbell, MD, MSPH; Charles Kooperberg, PhD; JoAnn E. Manson, MD, DrPH; Mary Jo O’Sullivan, MD, DrPH; Thomas Rohan, MBBS, PhD; Marcia L. Stefanick, PhD; Jean Wactawski-Wende, PhD; Heather Wakelee, MD; Michael S. Simon, MD, MPHS

25 ANNUAL REPORT 2015

Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients Katharina König, PhD; Martin Peifer; Jana Fassunke, PhD; Michaela A. Ihle, Dipl-Biol; Helen Künstlinger, Dpil-Biol; Carina Heydt, MSc; Katrin Stamm, PhD; Frank Ueckeroth; Claudia Vollbrecht, BSc; Marc Bos, MD; Masyar Gardizi, MD; Matthias Scheffler, MD; Lucia Nogova, MD; Frauke Leenders, MD; Kerstin Albus, MSc; Lydia Meder, MSc; Kerstin Becker, PhD; Alexandra Florin, MA; Ursula Rommerscheidt-Fuss; Janine Altmüller, PhD; Michael Kloth, MD; Nürnberg, Peter Prof; Thomas Henkel, PhD; Sven-Ernö Bikár, PhD; Martin L. Sos, PhD; William J. Geese, PhD; Lewis Strauss; Yon-Dschun Ko, MD; Ulrich Gerigk, MD; Margarete Odenthal, PhD; Thomas Zander, MD; Jürgen Wolf, Prof; Sabine Merkelbach-Bruse, MD; Reinhard Buettner, MD; Lukas C. Heukamp, PhD, MD

Tobacco Cessation May Improve Lung Cancer Patient Survival Katharine A. Dobson Amato, MPH, PhD; Andrew Hyland, PhD; Robert Reed, MPH; Martin C. Mahoney, MD, PhD; James Marshall, PhD; Gary Giovino, PhD; Maansi Bansal-Travers, PhD; Heather M. Ochs-Balcom, PhD; Michael A. Zevon, PhD; K. Michael Cummings, PhD; Chukwumere Nwogu, MD, PhD; Anurag K. Singh, MD; Hongbin Chen, MD, PhD; Graham W. Warren, MD, PhD; Mary Reid, PhD

Safety and Efficacy of Buparlisib (BKM120) in Patients With PI3K Pathway-Activated Non-Small Cell Lung Cancer (NSCLC): Results From the Phase II BASALT-1 Study Johan F. Vansteenkiste, MD, PhD; Jean-Luc Canon, MD; Filippo De Braud, MD; Francesco Grossi, MD; Tommaso De Pas, MD; Jhanelle E. Gray, MD; Wu-Chou Su, MD; Enriqueta Felip, MD, PhD; Hiroshige Yoshioka, MD; Cesare Gridelli, MD; Grace K. Dy, MD; Sumitra Thongprasert, MD; Martin Reck, MD, PhD; Paola Aimone, MD; Gena Atalla Vidam, MS, CPM; Pantelia Roussou, PhD; Ying A. Wang, PhD; Emmanuelle Di Tomaso, PhD; Jean-Charles Soria, MD, PhD

Profiling of oncogenic driver events in lung adenocarcinoma revealed MET mutation as independent prognostic factor Sai F. Yeung, BSc; Joanna Tong, H.M. PhD; Peggy Law, P.W. MPhil; Lau Y. Chung, AD; Lung, W.M. Raymond PhD; Carol Tong, Y.K. MPhil; Chit Chow, PhD; Anthony Chan, W.H. FRCPA; Innes Wan, Y.P. FRCS; Tony Mok, S.K. MD; Ka F. To, FRCPA

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non–Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens Luis Paz-Ares, MD; Vera Hirsh, MD; Li Zhang, MD; Filippo de Marinis, MD; James Chih-Hsin Yang, MD; Heather A. Wakelee, MD; Takashi Seto, MD; Yi-Long Wu, MD; Silvia Novello, MD; Erszébet Juhász, MD; Osvaldo Arén, MD; Yan Sun, MD; Thomas Schmelter, PhD; Teng Jin Ong, MD; Carol Peña, PhD; Egbert F. Smit, PhD; Tony S. Mok, MD

26 IASLC

Meetings IASLC members and staff work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. One of the most effective ways that this is accomplished is by offering cutting-edge educational meetings around the globe.

The 16th World Conference on Lung Cancer (WCLC), held Sept. 6-9 in Denver, Colorado, was a huge success.

2015 IASLC World Conference on Lung Cancer

WWW.IASLC.ORG

IASLC’s banner event of 2015 was the 16th World Conference on Lung Cancer (WCLC) held in Denver, Colorado, USA in early September. More than 6,000 researchers, physicians and specialists from nearly 100 countries came together to learn and share information about lung cancer.

The conference is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies and covers a wide range of disciplines, WELCOME including more than 300 invited talks and 3,000 TO THE IASLC formal research studies and clinical trial results.

16TH WORL D Every presentation at each WCLC aims to increase CONFERENC E ON LUNG awareness and collaboration so surgeons, medical CANCER oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses, allied health professionals, advocates, caregivers and patients understand the latest developments and can implement them throughout the world.

Conference Program Book FOLLOW US ON TWITTER @IASLC #WCLC2015

President and Co-Chairs

FOLLOW US ON FACEBOOK

BECOME A MEMBER OF IASLC

Fred R. Hirsch WCLC 2015 Congress President University of Colorado

VISIT WWW.IASLC.ORG

James Jett WCLC 2015 Congress Co-Chair National Jewish Health

Harvey Pass WCLC 2015 Congress Co-Chair NYU Langone Medical Center

Everett Vokes WCLC 2015 Congress Co-Chair The University of Chicago Medicine

27 ANNUAL REPORT 2015

For the first time, this year’s conference included lung cancer patients, survivors and caregivers. Additionally, the conference saw the release of IASLC’s new Tobacco Control and Smoking Cessation Statement (see page 21) and the culmination of two major IASLC initiatives: the Eighth Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer (page 19) and The WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition) (page 20).

This WCLC also featured the first ever Fun Walk and Pancake Breakfast. Around 300 people participated, including lung cancer patients, health professionals, patient advocates and more. The event raised nearly $20,000 for the IASLC Foundation.

The 2015 WCLC also marks the beginning of a new era for the IASLC. Instead of every two years, we will now host the WCLC annually. The 17th WCLC is set to take place in December 2016 in Vienna, Austria, and the 18th WCLC will be in Yokohama, Japan in October 2017.

Local Organizing Committee

Dara Aisner University of Colorado Anna Baron University of Colorado Paul A. Bunn, Jr. University of Colorado Tim Byers University of Colorado D. Ross Camidge University of Colorado Laurie Carr National Jewish Health Robert Doebele University of Colorado Wilbur Franklin University of Colorado Marileila Varella-Garcia University of Colorado Kavita Garg University of Colorado Laurie Gaspar University of Colorado Robert Jotte Rocky Mountain Cancer Centers

Brian Kavanagh University of Colorado Robert Keith University of Colorado Jeffrey Kern National Jewish Health Evi Makovsky Patient Advocate Dan Merrick University of Colorado York Miller University of Colorado John Mitchell University of Colorado Ana Oton University of Colorado David Raben University of Colorado Michael Weyant University of Colorado Samir Witta Mountain Blue Cancer Care Center

Nursing Pathology

28 IASLC

Basic Science Pharmacy

Diagnos c R Advocacy

WCLC 2015 By the Numbers »» More than 6,000 attendees »» From nearly 100 countries »» 2,122 abstracts submitted »» 258 oral abstracts presented »» 437 mini-oral abstracts presented »» 1,213 poster presentations »» 89 invited sessions

Biosta s cs

Hermatology

Smoking Ces

Demographic Distribution 60% 50% 40% 30% 20% 10% 0% Europe

North America

Asia

Rest of the World

Specialties of Delegates Medical Oncology Other

Medical Oncology

Thoracic Surgery Other

Pulmonary Medicine Thoracic Surgery Pulmonary Medicine Cancer Research Cancer Research

Radia on Oncology Radia on Oncology

Nursing Nursing

Pathology Pathology Basic Sciences

Basic Sciences Pharmacy

Pharmacy Diagnos c Radiology Advocacy Diagnos c Radiology Biosta s cs Advocacy

Hermatology

Biosta s cs

Smoking Cessa on

Hermatology Smoking Cessa on

29 ANNUAL REPORT 2015

Best of WCLC 2015 For those not able to attend the WCLC, IASLC continues to grow and expand the “Best of WCLC” events – educational initiatives which condense the timeliest scientific and educational topics from multiple disciplines into a one-day event and held throughout the world in 2015. IASLC partnered with local experts who crafted the agendas and focused on WCLC content to meet their regional needs.

Best of IASLC WCLC 2015 Location Turin, Italy Florence, Italy Bari, Italy San Francisco, USA Paris, France Oslo, Norway The Netherlands Guangdong, China Yokohama, Japan Prague, Czech Republic Salvador, Brazil Athens, Greece Seoul, Korea Lima, Peru Buenos Aires, Argentina Cancun, Mexico

Date September 2015 September 2015 September 2015 October 2015 October 2015 October 2015 October 2015 October 2015 November 2015 November 2015 December 2015 January 2016 January 2016 February 2016 March 2016 March 2016

Organizer/Chair Silvia Novello Silvia Novello Silvia Novello David Gandara Thierry le Chevalier Odd Terje Brustugun Quadia Group Chinese Thoracic Oncology Group Japan Lung Cancer Society Central European Lung Cancer Group Latin American Cooperative Group Konstantinos Syrigos Keunchil Park Grupo de Estudios Clinico Peruano Eduardo Richardet Mauro Molina Vargas

30 IASLC

IASLC Meetings in 2015 15th Annual Targeted Therapies of the Treatment of Lung Cancer This invitation-only meeting gathered the top scientists to discuss the latest advances in the treatment of lung cancer with targeted therapies.

February 18 – 21, 2015 | Santa Monica, CA Chairs: Paul A. Bunn, Jr., David H. Johnson and Roy Herbst # Participants: 450

European Lung Cancer Conference (ELCC) The European Society of Medical Oncology (ESMO) and the IASLC organized the ELCC, bringing together the top academic experts in lung cancer and thoracic malignancies to showcase the latest developments in basic, clinical and translational research.

April 15-18 2015 | Geneva, Switzerland Chairs: Dominique Grunenwald, France and Johan Vansteenkiste, Belgium # Participants: 1650 Small Cell Lung Cancer Two hundred global experts in SCLC met to review and refocus the field, to foster collaboration with the generation of new and innovative ideas for basic and clinical research, and to highlight the potential role for personalized medicine in SCLC clinical trial designs. A review publication from this meeting will be published in 2016.

April 22-24, 2015 | New York, NY Chairs: Charles Rudin, Fred R. Hirsch, Paul A. Bunn, Jr., John Minna, Glenwood Goss, Roman Thomas, Peter Ujhazy, Wolf Lindwasser, and Shakun Malik # Participants: 200

EGFR Expert Meeting A group of multidisciplinary experts including pathologists, pulmonologists, medical oncologists, thoracic surgeons, radiation oncologists, and diagnostic radiologists met to discuss how best to guide the lung cancer communities on molecular testing and clinical management of patients with EGFR mutated NSCLC, who have progressed on first-line EGFR TKI therapy for advanced disease.

August 1, 2015 | Huntington Beach, CA Chair: Fred R. Hirsch # Participants: 20

31 ANNUAL REPORT 2015

IASLC Endorsed and Supported Meetings in 2015 BTOG 2015 British Thoracic Oncology Group (BTOG) 13th Annual Conference January 28-30, 2015 | Dublin, Ireland 2015 Lung Cancer Workshop XII Prevent Cancer Foundation May 4-5, 2015 | Bethesda, MD 23rd European Conference on General Thoracic Surgery European Society of Thoracic Surgeons May 31-June 3, 2015 | Lisbon, Portugal

16th Annual International Lung Cancer Congress July 30 - August 1, 2015 | Huntington Beach, CA

4th Congress of Respiratory Medicine Institute for Pulmonary Diseases of Vojvodina Medical Faculty, University of Novi Sad and Clinic for Pulmonology, Clinical Center of Serbia October 15-18, 2015 | Novi Sad, Serbia Eighth Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung Cancer BioMedical Learning Institute (BMLI) October 17, 2015 | San Francisco, CA International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform Fibers Chairman: Michele Carbone November 9-10, 2015 | Honolulu, HI CELCC 2015 15th Central European Lung Cancer Conference November 28-30 2015 | Prague, Czech Republic

32 IASLC

Inter-Disciplinary Workshop to Enhance Assessment and Management of Lung Cancer IDEAL Workshop December 4, 2015 | Singapore 9th Annual Conference Polish Lung Cancer Group November 6-7, 2015 | Warsaw, Poland

2nd International Conference Asia Thoracoscopic Surgery Education Program (ATEP) December 4-5, 2015 | Seoul, Korea

2016 Meetings and Events 4th AACR-IASLC International Joint Conference The translational science featured at this conference will include the foundation of basic research that begins at the bench and continues through patient care in the clinic.

January 4 – 7, 2016 | San Diego, CA More details on www.iaslc.org 16th Annual Targeted Therapies of the Treatment of Lung Cancer This invitation-only meeting gathers the top scientists to discuss the latest advances in the treatment of lung cancer with targeted therapies.

February 17 – 20, 2016 | Santa Monica, CA More details on www.iaslc.org

European Lung Cancer Conference (ELCC) The European Society of Medical Oncology (ESMO) and the IASLC organize the ELCC, bringing together the top academic experts in lung cancer and thoracic malignancies to showcase the latest developments in basic, clinical and translational research.

April 13-16 2016 | Geneva, Switzerland More details on www.iaslc.org

33 ANNUAL REPORT 2015

IASLC Asia Pacific Lung Cancer Conference (APLCC 2016) The conference will bring you information in frontiers of clinical and basic researches, practical clinical management, and multidisciplinary care from Western and Asia-Pacific faculties.

May 13 - 16 2016 | Chiang Mai, Thailand More details on www.iaslc.org 2016 IASLC Latin American Lung Cancer Conference (LALCA) International and national speakers will discuss the science and advances in the treatment and prevention of lung cancer and thoracic malignancies worldwide and in Latin America in particular.

August 25 - 27 2016 | Panama City, Panama More details on www.iaslc.org IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology Co-chairs: Fred R. Hirsch, MD, PhD & Everett Vokes, MD. September 22-24 2016 | Chicago, IL More details on www.iaslc.org

17th IASLC World Conference on Lung Cancer The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies. More than 6,000 delegates come from nearly 100 countries to discuss the latest developments in thoracic malignancy research.

December 4-7 2016 | Vienna, Austria More details on www.iaslc.org

34 IASLC

IASLC 2015 Distinguished Awards The IASLC has four distinguished awards which were presented at the 2015 World Conference on Lung Cancer (WCLC).

Dr. Harvey Pass USA 2015 IASLC Merit Award

Dr. Yi-Long Wu China Paul A. Bunn, Jr. Scientific Award

Dr. Jacek Jassem Poland Joseph W. Cullen Prevention/ Early Detection Award

The IASLC Merit Award is given to a member of IASLC who has made an extraordinary contribution to the organization’s development. Dr. Harvey Pass received the 2015 IASLC Merit Award for his work as a surgeon scientist focusing on the early detection, surgical management and adjuvant therapy of thoracic malignancies. Dr. Pass has been continuously funded by the DOD, NCI, and the CDC among others since 1998 for the discovery and validation of blood-based biomarkers including osteopontin, soluble mesothelin related protein, and fibulin3. Dr. Pass has published over 450 peerreviewed publications, 11 books, including the IASLC Multidisciplinary Approach to Thoracic Oncology, and serves as an editor and on many editorial boards. Dr. Pass has been an active member of the IASLC since 1998, serving as the chair of the Publications Committee and the Co-Chair of the 2015 WCLC Local Organizing Committee among his other roles.

The Paul A. Bunn, Jr. Scientific Award is given to an IASLC scientist for lifetime scientific contributions in thoracic malignancy research and who has also contributed to the organization’s development. Dr. Yi-Long Wu’s main research interests are the multidisciplinary synthetic therapy on lung cancer from basic science to bedside and evidence-based medicine in oncology. His research mainly focuses on clinical and basic study of combined treatment of nonsmall cell lung cancer (NSCLC), especially in profiling the lung cancer tumors in Chinese patients for driver oncogenes and to build a tumor tissue bank across China, connected by a computer system. He is a leader in the Chinese lung cancer field and has been a Principal Investigator or Co-PI in more than 90 multi-center clinical trials.

He has contributed 20 books on cancer and has published more than 300 articles in peer-reviewed journals. Dr. Wu also serves on the IASLC Board of Directors.

The Joseph W. Cullen Prevention/Early Detection Award is given to an IASLC scientist for lifetime scientific achievements in prevention research of thoracic malignancies. Dr. Jacek Jassem heads the Department of Oncology and Radiotherapy at the Medical University of Gdansk, Poland.

His department’s research unit focuses on clinical trials and translational research combining cancer molecular features with clinical behavior.

The team has developed and validated novel tumor biomarkers in lung cancer and breast cancer, and shares a long term collaboration with the University of Colorado, publishing in the field of predictive assays for the potential benefits of targeted therapies in lung cancer.

Dr. Jassem is a member of the IASLC Tobacco Control and Smoking Cessation Committee and actively advises other countries on this topic.

Dr. Ming Tsao Canada Mary J. Matthews Pathology/ Translational Research Award The Mary J. Matthews Pathology/Translational Research Award is given to an IASLC scientist for lifetime scientific achievements in pathology-translational research of thoracic malignancies. Dr. Ming Tsao received this award for 2015.

Dr. Tsao’s primary goal in lung cancer research is to identify genes or proteins that are predictive of poor prognosis in lung cancer patients who have had their tumors resected by surgery.

His current lung cancer research activities include biomarkers in targeted cancer therapy, molecular prognostic and predictive markers and pathobiology of lung cancer, tumor cell stromal interaction, Ras oncogene, and application of novel optical/Raman technologies for tissue/cellular and in vivo imaging. Dr. Tsao has served on the Editorial Board of the JTO and as a member of the International Program Committee for three WCLCs.

35 ANNUAL REPORT 2015

IASLC WCLC 2015 Developing Nation Awards As recipients of the 2015 Developing Nation Awards, ten researchers from six developing nations received support to attend the WCLC in Denver, Colorado.

Recipient Bernadette Reyna Asuncion María Castillo Xiangkun Han Tomi Kovacevi Satya Narayan Blessing Obiazi-Odiase Emmanuel Odiase Cristina Perez Malcolm Tagbarha Qi Wang

Institution De La Salle University INCan Chinese Academy of Sciences Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad Acharya Tulsi Regional Cancer Treatment and Research Institute Children Life Advancement Project Nigerian Cancer Society National Cancer Institute of Brazil University of Abuja The Second Affiliated Hospital of Dalian Medical University

Country Philippines Mexico China Serbia India Nigeria Nigeria Brazil Nigeria China

IASLC WCLC 2015 Young Investigator Awards IASLC Young Investigator Awards are given to reward scientific excellence and to encourage innovative research in lung cancer prevention and translational medicine worldwide. The awards are open to IASLC members who are within three years of an initial faculty appointment at the time of application and within three years of completion of fellowship/postdoctoral training.

Recipient Lynnette Fernandez-Cuesta Yoshihisa Kobayashi Ji Yun Lee Clara Pérez-Rambla Tomasz Powrózek Brandon Sheffield Kenichi Suda Dana Tsui Dawei Yang Wenjing Zhang

Institution International Agency for Research on Cancer Kinki University Faculty of Medicine Samsung Medical Center Centro de Investigación Príncipe Felipe Medical University of Lublin University of British Columbia Kinki University Faculty of Medicine University of Cambridge Zhongshan Hospital Fudan University Chinese Academy of Sciences

Country France Japan South Korea Spain Poland Canada Japan England China China

36 IASLC

IASLC WCLC 2015 Advocacy Awards The IASLC WCLC 2015 Advocacy Awards are designed to increase connections with patient advocates and advocacy organizations around the world. An international panel selected the award winners for their leadership in supporting lung cancer research, patients and awareness worldwide.

Recipient Hildreth Grossman Seda Kansu Victor Lasebikan Kathleen Mewhiney Dan Powell Tetsuya Yamaoka

Role President/ Founder, Upstage Lung Cancer Co-founder, Pembe Hanim Psychiatrist and Lecturer, University of Ibadan Founder/President, The John & Amy Mewhiney Cancer Foundation Lung Cancer Survivor/Patient Advocate Lung Cancer Survivor/Patient Advocate

Location Brookline, Massachusetts Istanbul, Turkey Nigeria, Africa Silver Spring, Maryland Greenville, South Carolina Tokyo, Japan

IASLC WCLC 2015 Lectureships The IASLC recognized six investigators with IASLC WCLC 2015 Lectureship Awards for their high-ranking abstracts in key areas of lung cancer. These awards are named after IASLC members who have been leaders in their fields.

Award Adi Gazdar Lectureship Award (Translational Research) Robert Ginsberg Lectureship Award (Surgery)

Recipient Abstract Lynnette Fernandez-Cuesta, PhD “Genomic Characterization of Large Cell Neuroendocrine Lung Tumors” Virginie Westeel, MD “Compliance with Follow-Up Programs after Surgery for Non-Small Cell Lung Cancer in the Phase III IFCT-0302 Trial” Heine Hansen Lectureship Charles Rudin, MD, PhD “A DLL3-Targeted ADC, Award (Small Cell Lung Cancer) Rovalpituzumab Tesirine, Demonstrates Substantial Activity in a Phase I Study in Relapsed and Refractory SCLC” Dan Idhe Lectureship Award John Edwards, MD “Quality of Resection in Pathological (Medical Oncology) N2 NSCLC in the Phase 3 Lung Adjuvant Radiotherapy Trial (Lung ART): An Important Factor” Clifton Mountain Lectureship Edward Robbins, MD “Evolution in the Surgical Care of Award (Staging) Non-Small Cell Lung Cancer (NSCLC) Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort” Tsuguo Naruke Lectureship Ryutaro Kakinuma, MD “Natural History of Pulmonary Award (Surgery) Subsolid Nodules: A Prospective Multicenter Study”

37 ANNUAL REPORT 2015

IASLC WCLC 2015 International Mentorship Awards The International Mentorship Program, a new 2015 IASLC initiative, is a professional development and education program for early-career physicians/researchers studying thoracic malignancies from economically-developing countries. The awardees are matched with well-established scientific and clinical mentors from within the hosting WCLC region and visit the mentor’s institution for approximately a week following the WCLC.

Mentees with IASLC leadership at WCLC 2015

Recipient Rafael Bitton Saul Campos Gomez Juliano Ce Coelho Rania Aly Maria Jose Labanca Zoltan Lohinai Daniela Morales-Espinosa Ahmed Nagy Shengxiang “Harry” Ren Soumyajit Roy Phannin Tiraswasdichai Long Jiang Rajaram Burrah

Country Brazil Mexico Brazil Egypt Argentina Hungary Mexico Egypt China India Thailand China India

Mentor Suresh Ramalingam Charles Rudin Ramaswamy Govindan William Travis Marileila Varella-Garcia Paul A. Bunn, Jr. David Carbone Fred R. Hirsch/Theresa Boyle Ross Camidge Kavita Garg Alex Adjei John Mitchell Jessica Donington

IASLC would like to thank the following supporters of the IASLC 2015 International Mentorship Award Program: Astellas • AstraZeneca • Bristol-Myers Squibb • Clovis • Merck • Novartis

38 IASLC

2015 Sponsors We want to thank our sponsors for their generosity and support:

AbbVie Illumina Ariad Pharmaceuticals Janssen Pharma Astellas Pharma Merck AstraZeneca Myriad Biodesix Novartis Boehringer Ingelheim Pfizer Bristol-Myers Squibb Roche/Genentech Celgene Synta Pharmaceuticals Clovis Oncology Ventana Medical Daiichi Sankyo Systems Eli Lilly Verastem Elekta Vertex Helsinn Therapeutics Pharmaceuticals

2015 Advocacy Partners Lung Cancer Foundation of American (LCFA) Fellowship Partner Prevent Cancer Foundation - Fellowship Partner Addario Lung Cancer Foundation - Fellowship Partner American Lung Association (Colorado) Caring Ambassadors Lung Cancer Program Chris Draft Family Foundation Clifton F. Mountain Foundation Dusty Joy Foundation EX: Re-learn Live without Cigarettes Free Me From Lung Cancer Free to Breathe Global Lung Cancer Coalition Global Resource for Advancing Cancer Education (GRACE)

International Thoracic Oncology Nursing Forum John & Amy Mewhiney Cancer Foundation Lung Cancer Alliance Lung Cancer Research Foundation Lung Foundation Australia Lungevity Foundation Mesothelioma Applied Research Foundation My Cancer Genome Patients Rising Pembe Hanim UICC Global Cancer Control Community Union for International Cancer Control - UICC Upstage Lung Cancer Women Against Lung Cancer in Europe

39 ANNUAL REPORT 2015

Strategic Plan The mission of the IASLC is: »» To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies, »» To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public, and, »» To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world.

The IASLC Board of Directors approved an ambitious strategic plan for the organization in 2011 after a sixmonth process. IASLC staff still adheres to this plan, each year identifying numerous action items required to make significant steps toward achieving the plan.

In 2015, IASLC staff and members conducted the activities below to support the strategic plan and our mission.

Study GOAL 1 – IASLC embraces the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies. »» The IASLC Staging Committee developed the 8th Edition of the Staging of Lung Cancer.

With new classifications in Mesothelioma and Thymic malignancies, the new classifications are the most comprehensive ever. »» Together with the WHO, the IASLC Pathology Committee developed the new 2015 WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (Fourth edition). The IASLC is also working on new editions of the Atlas of ALK Testing in Lung Cancer and on a PD-L1 Atlas to guide immunotherapy.

40 IASLC

»» The 2015 World Conference on Lung Cancer (WCLC) in Denver had the most comprehensive tobacco control and smoking cessation program for any world conference, and included the launch of the Tobacco Control and Smoking Cessation Committee’s updated IASLC Statement on Tobacco Control and Smoking Cessation. The IASLC signed onto multiple policy letters related to tobacco control in 2015. »» The IASLC Prevention, Screening and Early Detection Committee held an all-day, sold-out workshop on planning for the implementation of lung cancer CT screening internationally at WCLC 2015. Committee members also created a standardized approach to establishing lung cancer screening clinics, to ensure worldwide consistency. Committee members wrote a document on establishing a lung cancer screening clinic, with the aim of helping centers through a standardized approach.

Education GOAL 2 - IASLC provides education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large and to the public. »» IASLC hosted a successful World Conference on Lung Cancer (WCLC) in Denver, highlighting groundbreaking science and expanding attendance to patients and advocates as well as health professionals. The IASLC will now host the WCLC every year, continuing in 2016 in Vienna, Austria, in Yokohama, Japan in 2017, in Toronto, Canada in 2018 and in Barcelona, Spain in 2019. »» IASLC used its recent accreditation to offer expanded and enhanced CME at many of our events. »» IASLC continued to build its educational webinars, offering more webinars on more topics and across more time zones than ever before.

41 ANNUAL REPORT 2015

»» The Education Committee developed multidisciplinary curriculum for fellows and young investigators, evaluated requests for IASLC endorsed meetings and developed Live Learning Programs which were initiated in 2015 and will continue in the future. »» IASLC initiated a new series of the “Best of WCLC” in the fall of 2015. With the help of local experts, IASLC provided the most significant updates from the WCLC to hundreds of participants in 18 international locations who were unable to attend the WCLC in Denver. »» The IASLC, along with Executive Editor Harvey I. Pass, MD, initiated work on a new edition of the IASLC Multidisciplinary Approach to Thoracic Oncology textbook set for publication in 2016. »» »» »» »» »» »» »» »» »» »» »»

Research and Science GOAL 3—IASLC advances research and science towards reducing the burden of thoracic malignancies worldwide. »» IASLC continues its funding of fellowships to promote scientific excellence and to encourage innovative research. This year IASLC supported 11 fellows in its program, continued a Chinese fellowship and partnered with the Bonnie J. Addario Foundation to create a large fellowship for the prevention and early detection of lung cancer.

»» The IASLC Journal of Thoracic Oncology continued to expand its coverage of the top translational and basic research and added significantly to its subscriber base while finalizing a deal with a new publisher, Elsevier.

Along with a new look, the move makes many new features available to our authors and readers. »» The JTO was ranked 30 out of 211 for oncology and 7 out of 57 for respiratory system subject matter categories in the 2014 Journal Citation Reports. The 2014 Impact Factor was 5.282. »» With the largest attendance ever, the IASLC 15th Annual Targeted Therapies in the Treatment of Lung Cancer in Santa Monica, Calif. in February gathered top scientists to discuss the latest advances in the treatment of lung cancer with targeted therapies. »» The year also saw a successful European Lung Cancer Conference (ELCC) in April and an announcement from IASLC and ESMO that the ELCC will become an annual meeting. »» IASLC also held focused meetings like one on Small Cell Lung Cancer in New York in April 2015 and an EGFR meeting in Huntington Beach, Calif. in August 2015. »» The Patient Advocates Committee launched several new initiatives including a Patient Advocacy Track at WCLC, unique registration rates for advocates, survivors and advocacy organizations, and creation of patient local liaisons and advocacy travel grants.

42 IASLC

Professional Membership Association

Organizational Growth GOAL 4 - IASLC is committed to long-term, global growth in membership. »» Meeting an aggressive goal of 5,000 active members in 2015, IASLC enrolled a record of more than 1,500 new members by the end of the year. »» While membership historically increases during WCLC years, IASLC improved the data sharing and registration process this year to capture membership as individuals completed WCLC registration. In addition, many new members took advantage of the multi-year discount offer at the WCLC in Denver. »» IASLC retained and recovered 88 percent of former members and lapsed members, which is an increase over past years’ retention rates. »» Increased promotion of the free Fellow membership, available to Fellows, Residents, and Trainees in all disciplines, led to growth in this member category. We encourage all members to “Invite-a-Fellow” or utilize the Group Fellow Registration to make sure early career physicians and investigators can benefit from this incredible value.

GOAL 5 - IASLC values the work of its volunteer members, who advance the IASLC mission through active participation and effective leadership. »» As a pilot program, IASLC launched a Membership Booth presence at societies for Thoracic Surgery, Pulmonology and Medical Oncology in Europe and North America, and we continue to increase IASLC exposure in under-represented specialties and regions of the world. »» IASLC established a goal of educating the entire team of providers for lung cancer patients, extending to pathologists, diagnostic radiologists, nurses and allied health professionals, community practitioners and industry professionals. To further that goal, IASLC updated its member communications to include language to make it clear that IASLC membership is valuable to anyone who is involved in lung cancer around the world. »» The IASLC Virtual Library launched in 2015 with educational content from WCLC 2015 and 2013 available to members on the IASLC website.

The 8th Edition TNM Staging Card Proposals continued to be offered, free of charge, at meetings around the world.

43 ANNUAL REPORT 2015

Charitable Giving and Philanthropic Relationships GOAL 6 - IASLC solicits philanthropic funds to support its research and educational programs. »» Central to the IASLC and the IASLC Foundation is the mission to support the education of fellows and young investigators. Since 2000, the IASLC has funded more than 80 fellowships, 11 in the most recent year. »» Through generous gifts to the IASLC Foundation, we can expand our fellowship program, creating more programs like the International Mentorship Program. »» In 2015, the Foundation had a strong start with donations large and small. We look forward to expanding donations to the Foundation in 2016 as we reach out to members and community partners.

Operational Soundness GOAL 7 - To accomplish its mission, the IASLC is committed to operational excellence and fiscal responsibility. »» The IASLC ends 2015 with a budget surplus for the year after responsibly managing the budget (slowly growing the asset base while remaining fiscally responsible) and after running a financially successful World Conference (WCLC 2015). »» Negotiating a contract with a new publisher for the JTO allows the IASLC to leverage new opportunities, to provide our members with information in new formats, and gives the organization a better revenue source from the Journal. »» Expansion of the “Best Of” series allows the most relevant and informative scientific data to be accessed by more people worldwide. »» IASLC has plans to grow the office by several new members (new space is leased and in the design phase and three of the new staff members began work in January 2016) in order to take advantage of new opportunities in this rapidly progressing field, and also to provide a better variety of services for our members.

44 IASLC

IASLC Foundation The IASLC Foundation’s mission is to support the education of fellows and young investigators destined to become the next generation of lung cancer physicians and scientists. Since 2000, the IASLC has funded 80 fellowships, 11 in the most recent year. With the help of the IASLC Foundation, we can expand this number in the future and assist more people in creating new and better ways to combat lung cancer.

To date members have donated over $250,000 to help fund these fellowships. With our expanded fundraising efforts, the sky is the limit. If you would like to donate to this worthy cause, please visit our website: iaslc.org/foundation.

In 2015, the Foundation had a strong start with a generous donation from Dr. Adi F. Gazdar. Relying on this substantial gift as seed money allows the IASLC Foundation to start funding our 2016 fellowships. However, this is just the start. We anticipate 2016 will see great strides as we grow our donation base.

Adi F. Gazdar

We are grateful for the contribution made by those on this full list of 2015 donors: $200,000 and above Adi F. Gazdar $3,000 - $5,000 Carolyn M. Dresler David R. Gandara Christian Manegold $1,000 - $3,000 Alex A. Adjei BioBridge Strategies (in honor of Denise Aberle, MD) Paul A. Bunn, Jr. David Paul Carbone Quincy Chu Ben Creelan Martin Edelman Jeffrey A. Engelman Edward B. Garon Peter Goldstraw David H. Harpole Fred R. Hirsch James R. Jett

Karen Kelly Aaron Mansfield John D. Minna Ron Natale Gregory A. Otterson Roman Perez-Soler Naiyer Rizvi Lee Rosen David R. Spigel Rolf Stahel Masahiro Tsuboi Volder Wacheck Glen and Lynne Weiss James Yang $500 - $1,000 Philip D. Bonomi Michael J. Boyer Julie Brahmer Jeffrey Crawford Jeremy J. Erasmus Laurie E. Gaspar Leora Horn

Mark G. Kris Christine Lovly Joel Neal Suresh S. Ramalingam Karen L. Reckamp Charles M. Rudin Nicole Ruiz Alan B. Sandler Sumitra Thongprasert Paul Van Houtte Nise Yamaguchi Under $500 Christian Adonizio Shaymaa Ahmed Newton Alves Naoko Aragane David Ball James Bartlett Lyudmia Bazhenova Susan Blackwell Alice Braae Giovanni L Carboni

45 ANNUAL REPORT 2015

Luis Eduardo Werneck Carvalho Guadalupe Cedillo Lee Choon-Taek Ljiljana Cilic Edward Conte Jeffrey M. Crane Jesus E. Davila Lars B. Drivsholm Wilfried E.E. Eberhardt Takashi Eto Etsuo Fujita Masahiro Fukuoka Adam Gamzon Arun Kumar Goel Jhanelle Gray Mark R. Green Tomasz Grodzki Zhongping Gu James U. Guachalla Toshiyuki Harada Masatoshi Hasegawa Kazushige Hayakawa Nina Helbekkmo Thomas A. Hensing Francisco M. Heralde III Shiori Hikawa Teodor Horvath Michael Humer Klaus L Irion Helgi J. Isaksson Dolores Isla Ming Lee Jang Sureerat Jaruhathai Takeshi Johkoh

Michael Jones Rosalyn Juergens Ryu Kanzaki Edward Kim Joo Hang Kim Ebenezer Kio Jiro Kitamura Katsuyuki Kiura Stephen C. Lam Corey J. Langer Yann Le Cocguic Jay M. Lee Jung Shin Lee Jang Ming Lee Natasha Leighl Rolf Lewensohn Tianhong Li Hamad Lia Katsuaki Maehara Manuel Magallanes Mitchell Magee Jo Ann Moran Marcelo Muino Silvia Novello Yuichiro Ohe Jiro Okami Meinoshin Okumura Maria C. Pietanza Robert Pirker Igor Polyakov Zhou Qing Neal Ready Kristin Richeimer Gregory Riely Barbara Ann Ryan

Lucianno H.P. Santos Arnold M. Schwartz David Shames Kazuhiko Shibata Arthur T Skarin Matthew Steliga Emily Stone Shigeki Sugiyama Minako Sumi Kenji Suzuki Irfan Tastepe Guillermo José Temperley Markus Tiemann Muge Tor Shinichi Toyooka William D. Travis Ming S. Tsao Rosaire Vaillancourt Paul Van Schil Gregory M.M. Videtic Maximilian von Laffert Heather Wakelee William Walsh John Wetherington Deborah A. Whippen Stephen K. Williamson Hiromasa Yamamoto David F. Yankelevitz Mei Ling Yap Xuchao Zhang Yong Zhang

IASLC Foundation Board David Carbone, Chair Fred R. Hirsch, CEO and Secretary David Gandara, Treasurer Giorgio Scagliotti, Member Tony Mok, Member

Ivar Samrén, Member Marc Braunstein, Member

The legacy of John Fisher John Fisher became ill in 2015 and rapidly passed away from mesothelioma, a thoracic cancer. His wife, Lauren, established a fund in his memory, John’s Legacy, honoring his life’s focus on making a difference in the lives of others. Two-thirds of the proceeds raised

by John’s Legacy will go toward the IASLC Foundation, specifically to aid in efforts based out of Colorado.

46 IASLC

Future Perspective (APLCC), and together with ESMO in Europe, the European Lung Cancer Meeting (ELCC).

The IASLC continues to focus on implementing new programs and initiatives that help support our members and our mission.

In the coming year, we will grow our membership and our activities, sharing more knowledge and best practices about lung cancer than ever before. In 2016, the IASLC will renew our focus on Asia while maintaining our high standards worldwide. This year marks the start of a new age – it will be the first time the World Conference on Lung Cancer is held annually and we look forward to seeing all of our members in Vienna in December 2016.

While we focus on the implementation of the annual WCLC, our commitments to regional activities will continue.

The IASLC will also expand on regional meetings in North America with our Chicago meeting, in Latin America with the Latin American Lung Cancer Meeting, (LALCA), in Asia with the Asian Pacific Lung Cancer Meeting

The IASLC also acknowledges the importance of having experts focusing on specific topics and providing guidance for future developments in specific areas, and therefore, we will expand our meeting portfolio to include smaller-focused meetings. We will also focus on providing guidance through scientific projects, such as the new PD-L1 Blueprint, and publications such as the revised ALK-ROS1 Atlas.

Our membership continues to expand, including advocates, patients, nurses and field representatives. We now have members in nearly 100 different countries as more people in our field recognize IASLC as the global leader in lung cancer.

The IASLC Foundation garners more support weekly as we continue to uncover outreach opportunities particularly in support of more fellowships and educational activities. In addition, as demand grows for the support from the IASLC staff, we will expand both the number of our staff and the size of the headquarters space.

In the coming year, we will continue to update the IASLC/ CAP/AMP guidelines for molecular testing for personalized therapy.

The IASLC, in conjunction with UICC, will publish the new (8th edition) staging system for intrathoracic tumors based on

work by the IASLC Pathology Committee. The committee will also widely distribute the new WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart.

In 2016, the IASLC hopes to establish a worldwide molecular database to provide investigators with opportunities to correlate numerous molecular abnormalities, many of which are rare, to clinical, demographic and treatment characteristics.Additionally, look for the arrival of other IASLC programs that will aid in communication between health professionals and patients and expand our reach.

The IASLC will also continue to host meetings across the globe, large and small, before we culminate with the WCLC in December. It is through these opportunities to share knowledge with each other that we can move the line in the fight against lung cancer.

We know that lung cancer screening can reduce lung cancer mortality significantly and is recommended for those defined as high-risk. The IASLC will continue to encourage more screening around the world. We are also looking to the future for new and better ways to detect thoracic malignancies earlier, as well as focusing on tobacco control and better prevention measures, as we continue our mission to reduce lung cancer mortality all over the world.

47 ANNUAL REPORT 2015

IASLC in Publications As the only global medical society dedicated to conquering thoracic malignances, IASLC’s activities, especially the WCLC, served as the basis for many publications and research studies in 2015. The following list contains citations of those publications as listed in PubMed, for the criteria “IASLC” or “International Association for the Study of Lung Cancer.” IASLC’s reputation and recognition continues to grow as members and non-members reference the organization in their work.

A proteomic profiling of laser-microdissected lung adenocarcinoma cells of early lepidictypes.

Kato Y, Nakamura H, Tojo H, Nomura M, Nagao T, Kawamura T, Kodama T, Ohira T, Ikeda N, Fehniger T, Marko-Varga G, Nishimura T, Kato H.

Clin Transl Med. 2015 Dec;4(1):64. doi: 10.1186/s40169-015-0064-3. Epub 2015 Jul 3.

Accuracy of the IASLC/ATS/ERS histological subtyping of stage I lung adenocarcinoma on intraoperative frozen sections.

Trejo Bittar HE, Incharoen P, Althouse AD, Dacic S.

Mod Pathol. 2015 Aug;28(8):1058-63. doi: 10.1038/modpathol.2015.71. Epub 2015 May 29.

Association between high-resolution computed tomography findings and the IASLC/ATS/ERS classification of small lung adenocarcinomas in Japanese patients.

Kudo Y, Matsubayashi J, Saji H, Akata S, Shimada Y, Kato Y, Kakihana M, Kajiwara N, Ohira T, Nagao T, Ikeda N.

Lung Cancer. 2015 Oct;90(1):47-54. doi: 10.1016/j.lungcan.2015.07.007. Epub 2015 Jul 26.

Association of IASLC/ATS/ERS Histologic Subtypes of Lung Adenocarcinoma With Epidermal Growth Factor Receptor Mutations in 320 Resected Cases.

Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, Takagi M.

Clin Lung Cancer. 2015 May;16(3):209-15. doi: 10.1016/j.cllc.2014.10.004. Epub 2014 Oct 25.

Change of junctions between stations 10 and 4 in the new International Association for the Study of Lung Cancer Lymph Node Map: a validation study from a single, tertiary referral hospital experience.

Lee S, Lee HY, Lee KS, Yie M, Zo J, Shim YM, Han J, Ahn JH.

Chest. 2015 May;147(5):1299-306. doi: 10.1378/chest.14-0717.

Clinical evaluation of a new tumour-nodemetastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group.

Fukui T, Fukumoto K, Okasaka T, Kawaguchi K, Nakamura S, Hakiri S, Ozeki N, Hirakawa A, Tateyama H, Yokoi K.

Eur J Cardiothorac Surg. 2015 Nov 7. doi:pii: ezv389. [Epub ahead of print]

Clinical impact of the new IASLC/ATS/ERS lung adenocarcinoma classification for chest surgeons.

Nakamura H, Takagi M.

Surg Today. 2015 Nov;45(11):1341-51. doi: 10.1007/s00595-014-1089-8. Epub 2014 Nov 23.

Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucoseuptake in positron emission tomography.

Nakamura H, Saji H, Shinmyo T, Tagaya R, Kurimoto N, Koizumi H, Takagi M.

Lung Cancer. 2015 Jan;87(1):28-33. doi: 10.1016/j.lungcan.2014.11.010. Epub 2014 Nov 27.

Close relation of large cell carcinoma to adenocarcinoma by hierarchical cluster analysis: implications for histologic typing of lung cancer on biopsies.

Hammer SH, Prall F.

Appl Immunohistochem Mol Morphol.

2015 Sep;23(8):550-7. doi: 10.1097/ PAI.0000000000000121.

Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification.

Weingertner N, Meyer N, Voegeli AC, Guenot D, Renaud S, Massard G, Falcoz PE, Olland A, Mennecier B, Gaub MP, Lindner V, Ghnassia JP, Quoix E, Chenard MP, Beau-Faller M.

Pathology. 2015 Jun;47(4):320-8. doi: 10.1097/PAT.0000000000000269.

48 IASLC

Correlations between pathologic subtypes/ immunohistochemical implication and CT characteristics of lung adenocarcinoma ≤ 1 cm with ground-glass opacity.

Wu F, Cai ZL, Tian SP, Jin X, Jing R, Yang YQ, Li YN, Zhao SH.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2015 Apr;37(2):163-70. doi: 10.3881/j.issn.1000503X.2015.02.006.

Cytopathology of pulmonary adenocarcinoma Rodriguez EF, Dacic S, Pantanowitz L, Khalbuss Cancer Cytopathol. 2015 May;123(5):306-17. with a single histological pattern using the WE, Monaco SE. doi: 10.1002/cncy.21532. Epub 2015 Mar 18. proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ ATS/ERS) classification.

Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer.

Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, Wang Z, Zhu Z, Deng Q, Xiong X, Shao W, Shi X, He J.

J Clin Oncol. 2015 Mar 10;33(8):861-9. doi: 10.1200/JCO.2014.56.6661. Epub 2015 Jan 26.

Diagnostic yield of endobronchial ultrasoundguided transbronchial needle aspiration for mediastinal staging in lung cancer.

Fernández-Bussy S, Labarca G, Canals S, Caviedes I, Folch E, Majid A.

J Bras Pneumol. 2015 May-Jun;41(3):219-24. doi: 10.1590/S1806-37132015000004466.

English, Spanish.

EGFR analysis: current evidence and future directions.

Bellevicine C, Malapelle U, de Luca C, Iaccarino A, Troncone G.

Diagn Cytopathol. 2014 Nov;42(11):984-92. doi: 10.1002/dc.23142. Epub 2014 Mar 12.

Review.

EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.

Yang Y, Yang Y, Zhou X, Song X, Liu M, He W, Wang H, Wu C, Fei K, Jiang G.

Lung Cancer. 2015 Mar;87(3):272-7. doi: 10.1016/j.lungcan.2014.12.016. Epub 2015 Jan 5.

Evaluation of the proposed International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancies Interest Group (ITMIG) staging revisions in thymic well-differentiated neuroendocrine carcinoma patients.

Zhao Y, Shi J, Fan L, Yang J, Hu D, Zhao H.

Eur J Cardiothorac Surg. 2015 May 1. doi:pii: ezv137. [Epub ahead of print]

Follow-up of patients after stereotactic radiation for lung cancer: a primer for the nonradiation oncologist.

Huang K, Palma DA; IASLC Advanced Radiation Technology Committee.

J Thorac Oncol. 2015 Mar;10(3):412-9. doi: 10.1097/JTO.0000000000000435.

Identifying Targeted Strategies to Improve Smoking Cessation Support for Cancer Patients.

Warren GW, Dibaj S, Hutson A, Cummings KM, Dresler C, Marshall JR.

J Thorac Oncol. 2015 Nov;10(11):1532-7. doi: 10.1097/JTO.0000000000000659.

Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.

Wang T, Zhang T, Han X, Liu XI, Zhou N, Liu Y.

Exp Ther Med. 2015 Jun;9(6):2095-2103.

Epub 2015 Apr 14.

International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma.

Yeh YC, Kadota K, Nitadori JI, Sima CS, Rizk NP, Jones DR, Travis WD, Adusumilli PS.

Eur J Cardiothorac Surg. 2015 Sep 15. doi:pii: ezv316. [Epub ahead of print]

Lung adenocarcinoma: Sustained subtyping with immunohistochemistry and EGFR, HER2 and KRAS mutational status.

Sousa V, Rodrigues C, Silva M, Alarcão AM, Carvalho L.

Rev Port Pneumol (2006). 2015 MayJun;21(3):113-25. doi: 10.1016/j. rppnen.2014.09.009. Epub 2015 Mar 11.

Lung cancer and concurrent or sequential lymphoma: Two case reports with hypersensitivity to bevacizumab and a review of the literature.

Pezzuto A, Piraino A, Mariotta S.

Oncol Lett. 2015 Feb;9(2):604-608. Epub 2014 Nov 20.

49 ANNUAL REPORT 2015

Metastatic index of non-small-cell lung cancer Poullis M, Shackcloth M, Page R, Asanti-Siaw and long-term survival.

J, Woolley S, Mediratta N.

Asian Cardiovasc Thorac Ann. 2015 Feb;23(2):185-90. doi: 10.1177/0218492314545833. Epub 2014 Aug 7.

Mitosis trumps T stage and proposed international association for the study of lung cancer/american thoracic society/ european respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma.

Duhig EE, Dettrick A, Godbolt DB, Pauli J, van Zwieten A, Hansen AR, Yang IA, Fong KM, Clarke BE, Bowman RV.

J Thorac Oncol. 2015 Apr;10(4):673-81. doi: 10.1097/JTO.0000000000000446.

Mitotic arrest deficient-like 1 is correlated with poor prognosis in small-cell lung cancer after surgical resection.

Li D, Meng Q, Zhang H, Feng T, Liu M, Cai L.

Tumour Biol. 2015 Oct 24. [Epub ahead of print]

Molecular alterations in non-small-cell lung cancer: perspective for targeted therapy and specimen management for the bronchoscopist.

Czarnecka-Kujawa K, Yasufuku K.

Respirology. 2014 Nov;19(8):1117-25. doi: 10.1111/resp.12377.

Molecular testing for selection of patients Rekhtman N, Leighl NB, Somerfield MR. with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/ association for molecular pathology guideline.

J Oncol Pract. 2015 Mar;11(2):135-6. doi: 10.1200/JOP.2014.002303. Epub 2014 Dec 16. No abstract available.

Multimodality therapy for locally advanced thymomas: A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database.

Leuzzi G, Rocco G, Ruffini E, Sperduti I, Detterbeck F, Weder W, Venuta F, Van Raemdonck D, Thomas P, Facciolo F; ESTS Thymic Working Group.

J Thorac Cardiovasc Surg. 2015 Aug 15. doi:pii: S0022-5223(15)01481-6. 10.1016/j. jtcvs.2015.08.034. [Epub ahead of print]

Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.

de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL.

Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1.

Nonpredominant lepidic pattern correlates with better outcome in invasive lung adenocarcinoma.

Mäkinen JM, Laitakari K, Johnson S, Mäkitaro R, Bloigu R, Lappi-Blanco E, Kaarteenaho R.

Lung Cancer. 2015 Oct 17. doi:pii: S0169-5002(15)30083-0. 10.1016/j. lungcan.2015.10.014. [Epub ahead of print]

Nuclear estrogen receptor-α expression is an independent predictor of recurrence in male patients with pT1aN0 lung adenocarcinomas, and correlates with regulatory T-cell infiltration.

Kadota K, Eguchi T, Villena-Vargas J, Woo KM, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Oncotarget. 2015 Sep 29;6(29):27505-18. doi: 10.18632/oncotarget.4752.

Outsourcing cytological samples to a referral laboratory for EGFR testing in non-small cell lung cancer: does theory meet practice?

Vigliar E, Malapelle U, Bellevicine C, de Luca C, Troncone G.

Cytopathology. 2015 Oct;26(5):312-7. doi: 10.1111/cyt.12221. Epub 2014 Nov 7.

Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura.

Raparia K, Villa C, Raj R, Cagle PT.

Arch Pathol Lab Med. 2015 Feb;139(2):18993. doi: 10.5858/arpa.2013-0759-OA. Epub 2014 Apr 2.

Perspectives of novel imaging techniques for staging, therapy response assessment, and monitoring of surveillance in lung cancer: summary of the Dresden 2013 Post WCLCIASLC State-of-the-Art Imaging Workshop.

Henzler T, Goldstraw P, Wenz F, Pirker R, Weder W, Apfaltrer P, Meyer M, Buesing K, Crino L, Fennell D, Fink C, Grunenwald D, Manegold C, Pilz L, Schoenberg SO, Suresh S, Vansteenkiste J, Voigt W, Wängler B, SchmidBindert G.

J Thorac Oncol. 2015 Feb;10(2):237-49. doi: 10.1097/JTO.0000000000000412.

50 IASLC

Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities.

Rami-Porta R, Asamura H, Goldstraw P.

Transl Lung Cancer Res. 2015 Aug;4(4):415-23. doi: 10.3978/j.issn.22186751.2015.07.11.

Prognostic impact and clinicopathological correlations of the cribriform pattern in pulmonary adenocarcinoma.

Warth A, Muley T, Kossakowski C, Stenzinger A, Schirmacher P, Dienemann H, Weichert W.

J Thorac Oncol. 2015 Apr;10(4):638-44. doi: 10.1097/JTO.0000000000000490.

Prognostic impact of pattern-based grading system by the new IASLC/ATS/ERS classification in Asian patients with stage I lung adenocarcinoma.

Zhao ZR, Xi SY, Li W, Situ DR, Chen KM, Yang H, Lung Cancer. 2015 Nov 4. doi:pii: Su XD, Lin YB, Long H. S0169-5002(15)30095-7. 10.1016/j. lungcan.2015.10.026. [Epub ahead of print]

Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.

Sun X, Wei P, Shen C, Yang Y, Wang Y, Li Y, Du X.

Am J Cancer Res. 2015;5(7):2266-76.

Prognostic value of the new IASLC/ATS/ ERS classification of clinical stage IA lung adenocarcinoma.

Murakami S, Ito H, Tsubokawa N, Mimae T, Sasada S, Yoshiya T, Miyata Y, Yokose T, Okada M, Nakayama H.

Lung Cancer. 2015 Nov;90(2):199-204. doi: 10.1016/j.lungcan.2015.06.022. Epub 2015 Jul 2.

Prognostic value of the new International Association for the Study of Lung Cancer/ American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma.

Xu CH, Wang W, Wei Y, Hu HD, Zou J, Yan J, Yu LK, Yang RS, Wang Y.

Eur J Surg Oncol. 2015 Oct;41(10):1430-6. doi: 10.1016/j.ejso.2015.06.004. Epub 2015 Jun 23.

Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?

Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR; IASLC Pathology Committee.

J Thorac Oncol. 2015 Jul;10(7):985-9. doi: 10.1097/JTO.0000000000000526.

Radiologic Evaluation of Small Lepidic Adenocarcinomas to Guide Decision Making in Surgical Resection.

Wilshire CL, Louie BE, Manning KA, Horton MP, Castiglioni M, Gorden JA, Aye RW, Farivar AS, Vallières E.

Ann Thorac Surg. 2015 Sep;100(3):979-88. doi: 10.1016/j.athoracsur.2015.04.030. Epub 2015 Jul 29.

Radiologic Predictors for Clinical Stage IA Lung Adenocarcinoma with Ground Glass Components: A Multi-Center Study of LongTerm Outcomes.

Li Z, Ye B, Bao M, Xu B, Chen Q, Liu S, Han Y, Peng M, Lin Z, Li J, Zhu W, Lin Q, Xiong L.

PLoS One. 2015;10(9):e0136616. doi: 10.1371/journal.pone.0136616.

Relationship between histopathologic characteristics and epidermal growth factor receptor mutation in lung adenocarcinoma.

Wang K, Gong H, Li X, Yang Z, Cao P, Wand C, Jiang Y, Wang H, Wang Y, Zhang G.

Zhonghua Bing Li Xue Za Zhi. 2015 Mar;44(3):170-4. Chinese.

Reproducibility of 3 histologic classifications and 3 staging systems for thymic epithelial neoplasms and its effect on prognosis.

Roden AC, Yi ES, Jenkins SM, Edwards KK, Donovan JL, Lewis JE, Cassivi SD, Marks RS, Garces YI, Aubry MC.

Am J Surg Pathol. 2015 Apr;39(4):427-41. doi: 10.1097/PAS.0000000000000391.

Role of CT and PET Imaging in Predicting Tumor Recurrence and Survival in Patients with Lung Adenocarcinoma: A Comparison with the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification of Lung Adenocarcinoma.

Lee HY, Lee SW, Lee KS, Jeong JY, Choi JY, Kwon J Thorac Oncol. 2015 Oct 15. [Epub ahead of OJ, Song SH, Kim EY, Kim J, Shim YM. print]

Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma.

Xu S, Xi J, Jiang W, Lu S, Wang Q.

Ann Thorac Surg. 2015 Mar;99(3):961-7. doi: 10.1016/j.athoracsur.2014.10.079. Epub 2015 Jan 27.

Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival.

Ujiie H, Kadota K, Chaft JE, Buitrago D, Sima CS, Lee MC, Huang J, Travis WD, Rizk NP, Rudin CM, Jones DR, Adusumilli PS.

J Clin Oncol. 2015 Sep 10;33(26):2877-84. doi: 10.1200/JCO.2015.60.9818. Epub 2015 Aug 10.

51 ANNUAL REPORT 2015

Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned.

Chang JY, Bezjak A, Mornex F; IASLC Advanced J Thorac Oncol. 2015 Apr;10(4):577-85. doi: Radiation Technology Committee.

10.1097/JTO.0000000000000453.

Subsolid pulmonary nodules: CT-pathologic correlation using the 2011 IASLC/ATS/ERS classification.

Liao JH, Amin VB, Kadoch MA, Beasley MB, Jacobi AH.

Clin Imaging. 2015 May-Jun;39(3):344-51. doi: 10.1016/j.clinimag.2014.12.009. Epub 2014 Dec 20. Review.

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, LeChevalier T, Pignon JP, Soria JC, Brambilla EM.

J Clin Oncol. 2015 Oct 20;33(30):3439-46. doi: 10.1200/JCO.2014.58.8335. Epub 2015 Apr 27.

The anaplastic lymphoma kinase testing conundrum.

Conde E, Taniere P, Lopez-Rios F.

Expert Rev Mol Diagn. 2015 Feb;15(2):161-3. doi: 10.1586/14737159.2015.997713. Epub 2015 Jan 12.

The clinical utility of Memorial Symptom Assessment-Short Form and Condensed Memorial Symptom Assessment Scale in Turkish lung cancer patients.

Yüceege M, Sanisoğlu B, Fırat H, Ersoy Y, Sevgi E, Kurt EB.

Clin Respir J. 2015 Apr;9(2):221-7. doi: 10.1111/crj.12127. Epub 2014 Mar 20.

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.

Eberhardt WE, Mitchell A, Crowley J, Kondo J Thorac Oncol. 2015 Nov;10(11):1515-22.

H, Kim YT, Turrisi A 3rd, Goldstraw P, Ramidoi: 10.1097/JTO.0000000000000673.

Porta R; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions.

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF Jr, Travis WD, Wu YL; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions.

J Thorac Oncol. 2015 Jul;10(7):990-1003. doi: 10.1097/JTO.0000000000000559.

The International Association for the Study of Lung Cancer Lymph Node Map: A Radiologic Atlas and Review.

Kim JH, van Beek EJ, Murchison JT, Marin A, Mirsadraee S.

Tuberc Respir Dis (Seoul). 2015 Jul;78(3):1809. doi: 10.4046/trd.2015.78.3.180. Epub 2015 Jun 30. Review.

The International Thymic Malignancy Interest Group thymic initiative: a state-of-the-art study of thymic malignancies.

Detterbeck F, Korst R.

Semin Thorac Cardiovasc Surg. 2014 Winter;26(4):317-22. doi: 10.1053/j. semtcvs.2015.02.002. Epub 2015 Feb 7.

Treatment of Peripheral Non-Small Cell Lung Carcinoma with Stereotactic Body Radiation Therapy.

Roach MC, Videtic GM, Bradley JD; IASLC Advanced Radiation Technology Committee.

J Thorac Oncol. 2015 Sep;10(9):1261-7. doi: 10.1097/JTO.0000000000000610.

Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma.

Kadota K, Buitrago D, Lee MC, Villena-Vargas J, Sima CS, Jones DR, Travis WD, Adusumilli PS.

Lung Cancer. 2015 Sep;89(3):329-36. doi: 10.1016/j.lungcan.2015.06.003. Epub 2015 Jun 15.

Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement.

Yeh YC, Nitadori J, Kadota K, Yoshizawa A, Rekhtman N, Moreira AL, Sima CS, Rusch VW, Adusumilli PS, Travis WD.

Histopathology. 2015 Jun;66(7):922-38. doi: 10.1111/his.12468. Epub 2015 Feb 5.

Utilization of the International Association for the Study of Lung Cancer and Wang’s nodal map for the identification of mediastinum and hilar lymph nodes.

Xia Y, Ma Y, Arias S, Lee H, Wang KP.

Thorac Cancer. 2015 Jul;6(4):464-8. doi: 10.1111/1759-7714.12206. Epub 2015 Jan 8.

Video-assisted thoracoscopic surgery lobectomy for lung cancer is associated with a lower 30-day morbidity compared with lobectomy by thoracotomy.

Laursen LØ, Petersen RH, Hansen HJ, Jensen TK, Ravn J, Konge L.

Eur J Cardiothorac Surg. 2015 Jun 18. doi:pii: ezv205. [Epub ahead of print]

52 IASLC

13100 East Colfax Avenue, Unit 10 | Auora, Colorado, USA 80011 | www.iaslc.org